jivox31595@dyleris.com
It looks like you've shared an email address. How can I help you with it? Are you looking to:
- Sign up / register for something using this address?
- Report spam or phishing from this domain?
- Look up information about the domain
dyleris.com? - Something else entirely?
Let me know what you need!
Make me a detailed ppt on a case presentation of peripheral vascular disease for my pg general surgery presentation from standard surgery practical and theory books covering all the viva questions
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Good - I have the surgery books. Now let me search for peripheral vascular disease content across all of them in parallel.
Finding Sources
Finding Sources
Now let me extract detailed content from the key surgery textbooks - Bailey & Love, Sabiston, Schwartz, S. Das, and also search for specific PVD topics:
Finding Sources
Finding Sources
Now let me extract detailed content from the key sources simultaneously:
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I have rich content. Now let me read more critical sections - Fontaine's classification, chronic ischemia, and Buerger's disease from S. Das and Bailey & Love:
Reading File
Reading File
Now let me get the chronic limb ischemia classification (Fontaine) and the S. Das content on chronic occlusion and surgical management:
Reading File
I now have comprehensive content. Let me update the todos and build the PPT:
Running Command
mkdir -p /home/daytona/workspace/pvd-presentation && ls /home/daytona/workspace/pvd-presentation
Writing File
~/pvd-presentation/pvd_ppt.js
const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_WIDE";
pres.title = "Peripheral Vascular Disease - Case Presentation";
pres.author = "PG General Surgery";
// ─── PALETTE ───────────────────────────────────────────────────────────────
const C = {
darkBg: "0A1628", // deep navy
midBg: "112240", // slightly lighter navy
accent: "E63946", // arterial red
accentSoft:"C1121F", // deeper red
gold: "F4A261", // warm amber / highlight
lightText: "EDF2F4", // near-white
subText: "A8DADC", // teal-gray
white: "FFFFFF",
tableHdr: "C1121F",
tableBand: "1A2F4F",
green: "2DC653",
yellow: "FFD166",
};
// ─── HELPERS ─────────────────────────────────────────────────────────────────
function addSlideHeader(slide, title, sub) {
// dark top bar
slide.addShape(pres.ShapeType.rect, {
x:0, y:0, w:13.3, h:0.85,
fill: { color: C.accent }
});
slide.addText(title.toUpperCase(), {
x:0.25, y:0.05, w:12.8, h:0.75,
fontSize:22, bold:true, color:C.white,
fontFace:"Calibri", align:"left", valign:"middle", margin:0
});
if (sub) {
slide.addText(sub, {
x:0.25, y:0.83, w:12.8, h:0.32,
fontSize:11, color:C.subText, italic:true,
fontFace:"Calibri", align:"left", valign:"middle", margin:0
});
}
// bottom bar
slide.addShape(pres.ShapeType.rect, {
x:0, y:7.25, w:13.3, h:0.25,
fill: { color: C.accentSoft }
});
slide.addText("PG General Surgery Case Presentation | Peripheral Vascular Disease", {
x:0.2, y:7.26, w:12.9, h:0.2,
fontSize:8, color:C.white, fontFace:"Calibri", align:"left", valign:"middle", margin:0
});
}
function bulletSlide(slide, items, x, y, w, h, opts={}) {
const rows = items.map((it, i) => {
const isLast = i === items.length - 1;
return {
text: (it.indent ? " \u25E6 " : "\u25CF ") + it.text,
options: {
fontSize: opts.fontSize || 14,
color: it.highlight ? C.gold : (it.indent ? C.subText : C.lightText),
bold: it.bold || false,
breakLine: !isLast,
fontFace: "Calibri"
}
};
});
slide.addText(rows, { x, y, w, h, valign:"top", margin:4 });
}
// ─── SLIDE 1: TITLE ─────────────────────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
// decorative arc
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:4.5, h:7.5, fill:{ color:C.midBg } });
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:4.5, h:0.06, fill:{ color:C.accent } });
// left panel text
s.addText("CASE\nPRESENTATION", {
x:0.2, y:0.6, w:4.1, h:2.0,
fontSize:28, bold:true, color:C.accent, fontFace:"Calibri",
align:"center", valign:"middle"
});
s.addText([
{ text: "PG General Surgery", options:{ fontSize:13, color:C.subText, breakLine:true } },
{ text: "Department of Surgery", options:{ fontSize:12, color:C.subText } }
], { x:0.2, y:6.8, w:4.1, h:0.6, align:"center", fontFace:"Calibri" });
// main title
s.addText("PERIPHERAL\nVASCULAR\nDISEASE", {
x:5.0, y:1.0, w:7.9, h:3.5,
fontSize:44, bold:true, color:C.lightText,
fontFace:"Calibri", align:"left", valign:"middle"
});
s.addShape(pres.ShapeType.rect, { x:5.0, y:4.6, w:7.5, h:0.06, fill:{ color:C.accent } });
s.addText("A Comprehensive Clinical Review", {
x:5.0, y:4.7, w:7.9, h:0.5,
fontSize:16, color:C.gold, fontFace:"Calibri", italic:true
});
s.addText([
{ text: "Sources: ", options:{ bold:true, color:C.gold } },
{ text: "Bailey & Love 28e • S. Das Manual of Clinical Surgery 13e\nSchwartz's Principles of Surgery 11e • Sabiston Textbook of Surgery\nCurrent Surgical Therapy 14e", options:{ color:C.subText } }
], { x:5.0, y:5.4, w:8.0, h:1.6, fontSize:11, fontFace:"Calibri" });
}
// ─── SLIDE 2: CASE VIGNETTE ──────────────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Case Vignette", "Setting the Clinical Stage");
s.addShape(pres.ShapeType.rect, { x:0.3, y:1.05, w:12.7, h:5.9, fill:{ color:C.midBg }, line:{ color:C.accent, pt:1.5 } });
s.addText("PRESENTING COMPLAINT", {
x:0.5, y:1.15, w:12.3, h:0.35,
fontSize:12, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
s.addText([
{ text: "Mr. X", options:{ bold:true, color:C.gold } },
{ text: ", 58-year-old male, chronic smoker (40 pack-years), known diabetic & hypertensive,\npresents with:", options:{ color:C.lightText } }
], { x:0.5, y:1.55, w:12.3, h:0.75, fontSize:13, fontFace:"Calibri" });
const complaints = [
{ text: "Pain in both calves on walking ~200 metres — relieved by rest (claudication distance: 200 m)", bold:true },
{ text: "Pain at rest in left foot for the past 3 weeks, worse at night, partially relieved by hanging the foot down" },
{ text: "Non-healing ulcer on the dorsum of left foot — present for 6 weeks" },
{ text: "Blackish discolouration of left 1st toe — noticed 2 weeks ago" },
];
bulletSlide(s, complaints, 0.5, 2.3, 12.3, 2.2, { fontSize:13 });
s.addText("RELEVANT HISTORY", {
x:0.5, y:4.55, w:12.3, h:0.35,
fontSize:12, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
const hist = [
{ text: "DM Type 2 — 12 years, on oral hypoglycaemics; Hypertension — 8 years; Smoker since age 18" },
{ text: "H/o similar but milder claudication symptoms 2 years ago — managed conservatively" },
{ text: "No h/o trauma, cardiac surgery, or previous vascular intervention" },
];
bulletSlide(s, hist, 0.5, 4.95, 12.3, 1.8, { fontSize:12 });
}
// ─── SLIDE 3: DEFINITIONS & CLASSIFICATION ───────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Definitions & Classification", "Bailey & Love 28e | S. Das 13e");
// Definition box
s.addShape(pres.ShapeType.rect, { x:0.3, y:1.1, w:12.7, h:1.3, fill:{ color:C.midBg }, line:{ color:C.accent, pt:1.5 } });
s.addText([
{ text: "DEFINITION ", options:{ bold:true, color:C.gold } },
{ text: "Peripheral Vascular Disease (PVD) is a spectrum of disorders of the peripheral circulation arising from structural or functional abnormalities of the arteries, veins, or lymphatics — most commonly due to atherosclerosis causing chronic ischaemia of the lower limbs.", options:{ color:C.lightText } }
], { x:0.5, y:1.15, w:12.3, h:1.15, fontSize:12.5, fontFace:"Calibri", valign:"middle" });
// Fontaine Classification table
s.addText("FONTAINE'S CLASSIFICATION (Chronic Limb Ischaemia)", {
x:0.3, y:2.55, w:12.7, h:0.35,
fontSize:12, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
const fontaineRows = [
["Stage", "Clinical Features", "ABI"],
["Stage I", "Asymptomatic — vessel disease present but no symptoms", "> 0.9"],
["Stage IIa", "Mild claudication — claudication distance > 200 m", "0.7 – 0.9"],
["Stage IIb", "Moderate-severe claudication — distance ≤ 200 m", "0.5 – 0.7"],
["Stage III", "Ischaemic rest pain — nocturnal, relieved by dependency", "< 0.5"],
["Stage IV", "Ulceration / Gangrene — tissue loss, non-healing wounds", "< 0.3"],
];
s.addTable(fontaineRows.map((row, ri) => row.map((cell, ci) => ({
text: cell,
options: {
bold: ri === 0,
color: ri === 0 ? C.white : (ri >= 4 ? C.gold : C.lightText),
fill: ri === 0 ? C.tableHdr : (ri % 2 === 0 ? C.tableBand : C.midBg),
align: ci === 0 ? "center" : "left",
fontSize: ri === 0 ? 12 : 11,
fontFace:"Calibri"
}
}))), { x:0.3, y:2.95, w:12.7, colW:[1.5, 8.5, 2.7], rowH:0.42, border:{ type:"solid", color:"334466", pt:0.5 } });
s.addText("Rutherford Classification also widely used (Categories 0–6, Classes I–III) — correlates with Fontaine stages", {
x:0.3, y:5.75, w:12.7, h:0.35,
fontSize:10.5, color:C.subText, italic:true, fontFace:"Calibri"
});
// TASC II note
s.addShape(pres.ShapeType.rect, { x:0.3, y:6.15, w:12.7, h:0.85, fill:{ color:"1A2F4F" }, line:{ color:C.gold, pt:1 } });
s.addText([
{ text: "TASC II Classification", options:{ bold:true, color:C.gold } },
{ text: " — Classifies lesions A–D based on morphology for endovascular vs. surgical decision making:\n", options:{ color:C.lightText } },
{ text: "Type A: single stenosis <3 cm → best for PTA | Type D: extensive disease → surgery preferred", options:{ color:C.subText, italic:true } }
], { x:0.5, y:6.18, w:12.3, h:0.8, fontSize:11, fontFace:"Calibri", valign:"middle" });
}
// ─── SLIDE 4: AETIOLOGY & RISK FACTORS ──────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Aetiology & Risk Factors", "Schwartz 11e | Bailey & Love 28e");
// Left column
s.addShape(pres.ShapeType.rect, { x:0.3, y:1.1, w:6.1, h:5.9, fill:{ color:C.midBg }, line:{ color:C.accent, pt:1 } });
s.addText("CAUSES OF PVD", {
x:0.5, y:1.15, w:5.7, h:0.38, fontSize:13, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
const causes = [
{ text: "OCCLUSIVE (commonest)", bold:true, highlight:true },
{ text: "Atherosclerosis — most common cause (>90%)", indent:true },
{ text: "Thromboangiitis obliterans (Buerger's disease)", indent:true },
{ text: "Arterial embolism (acute)", indent:true },
{ text: "Acute-on-chronic thrombosis", indent:true },
{ text: "INFLAMMATORY / VASCULITIS", bold:true, highlight:true },
{ text: "Takayasu's arteritis", indent:true },
{ text: "Temporal (giant cell) arteritis", indent:true },
{ text: "Polyarteritis nodosa, SLE, RA", indent:true },
{ text: "FUNCTIONAL / VASOSPASTIC", bold:true, highlight:true },
{ text: "Raynaud's disease / syndrome", indent:true },
{ text: "Acrocyanosis, livedo reticularis", indent:true },
{ text: "OTHER", bold:true, highlight:true },
{ text: "Popliteal entrapment, cystic adventitial disease", indent:true },
{ text: "Cervical rib / thoracic outlet syndrome", indent:true },
];
bulletSlide(s, causes, 0.5, 1.6, 5.7, 5.2, { fontSize:11.5 });
// Right column
s.addShape(pres.ShapeType.rect, { x:6.9, y:1.1, w:6.1, h:5.9, fill:{ color:C.midBg }, line:{ color:C.gold, pt:1 } });
s.addText("RISK FACTORS (Atherosclerosis)", {
x:7.1, y:1.15, w:5.7, h:0.38, fontSize:13, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
const riskRows = [
["NON-MODIFIABLE", ""],
["Age >50 years", "Male gender"],
["Family history", "Race (higher in S. Asians)"],
["MODIFIABLE", ""],
["Cigarette smoking*", "Diabetes mellitus*"],
["Hypertension", "Hyperlipidaemia"],
["Obesity / sedentary", "Hypercoagulable states"],
["Homocysteinaemia", "CKD / Renal disease"],
];
s.addTable(riskRows.map((row, ri) => row.map((cell) => ({
text: cell,
options: {
bold: (cell === "NON-MODIFIABLE" || cell === "MODIFIABLE"),
color: (cell === "NON-MODIFIABLE" || cell === "MODIFIABLE") ? C.white : C.lightText,
fill: (cell === "NON-MODIFIABLE" || cell === "MODIFIABLE") ? C.accentSoft : (ri % 2 === 0 ? C.tableBand : C.midBg),
fontSize:11.5, fontFace:"Calibri"
}
}))), { x:6.9, y:1.6, w:6.1, colW:[3.05, 3.05], rowH:0.42, border:{ type:"solid", color:"334466", pt:0.5 } });
s.addShape(pres.ShapeType.rect, { x:6.9, y:5.5, w:6.1, h:1.3, fill:{ color:"1A2F4F" }, line:{ color:C.accent, pt:1 } });
s.addText([
{ text: "* SMOKING", options:{ bold:true, color:C.accent } },
{ text: " is the single most important risk factor — 3–4× increased risk of PVD\n", options:{ color:C.lightText } },
{ text: "* DIABETES", options:{ bold:true, color:C.accent } },
{ text: " causes distal small vessel disease predominantly — below-knee vessels\nABI may be falsely elevated in diabetes due to calcified incompressible vessels", options:{ color:C.subText } }
], { x:7.1, y:5.55, w:5.7, h:1.2, fontSize:11, fontFace:"Calibri", valign:"top" });
}
// ─── SLIDE 5: PATHOPHYSIOLOGY ────────────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Pathophysiology", "Robbins Pathology | Schwartz 11e | Sabiston");
s.addText("ATHEROSCLEROSIS — THE UNDERLYING MECHANISM", {
x:0.3, y:1.0, w:12.7, h:0.35,
fontSize:12, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
// Flow diagram boxes
const steps = [
{ label: "1. Endothelial Injury", detail: "Turbulent flow at\nbifurcations, smoking,\nDM, HTN → injury" },
{ label: "2. Lipid Deposition", detail: "LDL enters intima\nOxidised LDL triggers\ninflammatory cascade" },
{ label: "3. Foam Cells", detail: "Macrophages ingest\nox-LDL → foam cells\n→ fatty streaks" },
{ label: "4. Fibrous Plaque", detail: "SMC proliferation\nCollagen deposition\nFibrous cap forms" },
{ label: "5. Calcification", detail: "Complex plaque with\ncalcium, necrotic core\n→ stenosis/occlusion" },
];
steps.forEach((step, i) => {
const x = 0.3 + i * 2.5;
s.addShape(pres.ShapeType.rect, { x, y:1.5, w:2.3, h:1.8, fill:{ color:C.midBg }, line:{ color:C.accent, pt:1.5 } });
s.addText(step.label, { x, y:1.5, w:2.3, h:0.5, fontSize:11, bold:true, color:C.gold, fontFace:"Calibri", align:"center", valign:"middle" });
s.addText(step.detail, { x, y:2.0, w:2.3, h:1.3, fontSize:10, color:C.lightText, fontFace:"Calibri", align:"center", valign:"top" });
if (i < 4) {
s.addText("→", { x: x+2.3, y:2.1, w:0.2, h:0.6, fontSize:18, color:C.accent, align:"center", valign:"middle", fontFace:"Calibri" });
}
});
s.addText("CONSEQUENCES OF ARTERIAL OCCLUSION", {
x:0.3, y:3.55, w:12.7, h:0.35,
fontSize:12, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
// Two columns
s.addShape(pres.ShapeType.rect, { x:0.3, y:4.0, w:6.1, h:3.2, fill:{ color:C.midBg }, line:{ color:C.accent, pt:1 } });
s.addText("Haemodynamic Effects", {
x:0.5, y:4.05, w:5.7, h:0.35, fontSize:12, bold:true, color:C.accent, fontFace:"Calibri"
});
const haemo = [
{ text: "Stenosis >50% → significant pressure gradient" },
{ text: "Critical stenosis >75% → resting ischaemia" },
{ text: "ABI (ABPI) falls below 1.0 — diagnostic" },
{ text: "Collateral vessels develop (Profunda femoris → popliteal)" },
{ text: "Reactive hyperaemia impaired (Buerger's sign)" },
];
bulletSlide(s, haemo, 0.5, 4.45, 5.7, 2.5, { fontSize:11.5 });
s.addShape(pres.ShapeType.rect, { x:6.9, y:4.0, w:6.1, h:3.2, fill:{ color:C.midBg }, line:{ color:C.gold, pt:1 } });
s.addText("Tissue Consequences", {
x:7.1, y:4.05, w:5.7, h:0.35, fontSize:12, bold:true, color:C.gold, fontFace:"Calibri"
});
const tissue = [
{ text: "Anaerobic metabolism → lactic acid → claudication pain" },
{ text: "Oxygen demand exceeds supply at rest → rest pain" },
{ text: "Skin & subcutaneous tissue most vulnerable" },
{ text: "Muscle loses bulk → wasting, weakness" },
{ text: "Neuropathy (in DM) masks pain → silent ischaemia" },
{ text: "Ulceration → infection → gangrene (dry or wet)" },
];
bulletSlide(s, tissue, 7.1, 4.45, 5.7, 2.5, { fontSize:11.5 });
}
// ─── SLIDE 6: CLINICAL FEATURES ──────────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Clinical Features — History & Symptoms", "S. Das 13e | Bailey & Love 28e");
// Symptoms table
s.addText("CARDINAL SYMPTOMS OF CHRONIC LIMB ISCHAEMIA", {
x:0.3, y:1.0, w:12.7, h:0.35,
fontSize:12, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
const sympRows = [
["Symptom", "Description", "Stage"],
["Intermittent Claudication", "Muscle pain / cramping on walking; relieved by rest in <5 min; reproducible at same distance", "IIa–IIb"],
["Rest Pain", "Burning/aching in foot & toes; worse at night (lying down); relieved by dependency (hanging foot down) — Buerger's dependency test", "III"],
["Non-healing Ulcers", "Punched-out arterial ulcers on pressure areas — toes, heel, malleoli; painful (unlike venous)", "IV"],
["Gangrene", "Dry gangrene (mummification) or Wet gangrene (infection); blackened, demarcated tissue", "IV"],
["Impotence (males)", "Leriche syndrome: aorto-iliac occlusion — bilateral claudication + absent femoral pulses + impotence", "Special"],
];
s.addTable(sympRows.map((row, ri) => row.map((cell, ci) => ({
text: cell,
options: {
bold: ri === 0,
color: ri === 0 ? C.white : (ci === 2 ? C.gold : C.lightText),
fill: ri === 0 ? C.tableHdr : (ri % 2 === 0 ? C.tableBand : C.midBg),
fontSize: ri === 0 ? 12 : 11,
fontFace:"Calibri",
align: ci === 2 ? "center" : "left"
}
}))), { x:0.3, y:1.4, w:12.7, colW:[2.8, 7.7, 2.2], rowH:0.48, border:{ type:"solid", color:"334466", pt:0.5 } });
// Important viva point
s.addShape(pres.ShapeType.rect, { x:0.3, y:4.95, w:12.7, h:1.4, fill:{ color:"1A2F4F" }, line:{ color:C.gold, pt:1.5 } });
s.addText([
{ text: "VIVA POINT — Claudication vs. Rest Pain vs. Other Leg Pain:\n", options:{ bold:true, color:C.gold } },
{ text: "Claudication — walking ◈ | Venous claudication — worse on standing, requires elevation for relief ◈ | Neurogenic claudication — flexing spine (leaning forward on trolley) relieves pain ◈ | Rest pain — worse supine, relieved by dependency in arterial disease", options:{ color:C.lightText } }
], { x:0.5, y:5.0, w:12.3, h:1.3, fontSize:11.5, fontFace:"Calibri", valign:"top" });
s.addText("Leriche Syndrome (Aorto-iliac occlusion): Bilateral claudication buttock/thigh + absent femoral pulses + impotence", {
x:0.3, y:6.45, w:12.7, h:0.45,
fontSize:11.5, color:C.accent, bold:true, fontFace:"Calibri", italic:true
});
}
// ─── SLIDE 7: CLINICAL EXAMINATION ───────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Clinical Examination — Signs", "S. Das 13e | Bailey & Love 28e");
// Left column: Inspection
s.addShape(pres.ShapeType.rect, { x:0.3, y:1.1, w:4.0, h:5.85, fill:{ color:C.midBg }, line:{ color:C.accent, pt:1 } });
s.addText("INSPECTION", {
x:0.5, y:1.15, w:3.6, h:0.38, fontSize:12, bold:true, color:C.accent, fontFace:"Calibri", charSpacing:2
});
const inspection = [
{ text: "Colour: pallor / cyanosis / blackening" },
{ text: "Skin: shiny, hairless, dry skin" },
{ text: "Trophic changes: thickened nails" },
{ text: "Muscle wasting of calf & thigh" },
{ text: "Ulceration: site, base, edge" },
{ text: "Gangrene: wet vs dry, extent" },
{ text: "Venous guttering (veins collapse)" },
{ text: "Buerger's angle (normal >45°)" },
{ text: "Capillary refilling — slow or absent" },
{ text: "Colour change on elevation (pallor) and dependency (dusky redness)" },
];
bulletSlide(s, inspection, 0.5, 1.6, 3.6, 5.2, { fontSize:11 });
// Middle column: Palpation
s.addShape(pres.ShapeType.rect, { x:4.7, y:1.1, w:4.0, h:5.85, fill:{ color:C.midBg }, line:{ color:C.gold, pt:1 } });
s.addText("PALPATION", {
x:4.9, y:1.15, w:3.6, h:0.38, fontSize:12, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
const palpation = [
{ text: "Temperature — cold limb (dorsum of hand)" },
{ text: "Capillary refilling — >2 sec abnormal" },
{ text: "PULSES — systematically:" },
{ text: "Femoral: below midinguinal point", indent:true },
{ text: "Popliteal: knee flexed 40°, firm pressure", indent:true },
{ text: "Post. tibial: behind medial malleolus", indent:true },
{ text: "Dorsalis pedis: lat to EHL tendon*", indent:true },
{ text: "(*absent in 10% of normal population)", indent:true },
{ text: "Tenderness of calf muscles" },
{ text: "Bruit palpable as thrill" },
{ text: "Pulsatile mass → aneurysm" },
];
bulletSlide(s, palpation, 4.9, 1.6, 3.6, 5.2, { fontSize:11 });
// Right column: Special Tests
s.addShape(pres.ShapeType.rect, { x:9.1, y:1.1, w:3.9, h:5.85, fill:{ color:C.midBg }, line:{ color:C.subText, pt:1 } });
s.addText("SPECIAL TESTS", {
x:9.2, y:1.15, w:3.5, h:0.38, fontSize:12, bold:true, color:C.subText, fontFace:"Calibri", charSpacing:2
});
const special = [
{ text: "BUERGER'S TEST:", bold:true, highlight:true },
{ text: "Raise leg: pallor at angle of ischaemia (<15° = critical)", indent:true },
{ text: "Hang leg down: reactive hyperaemia (guttered veins refill >15s → ischaemia)", indent:true },
{ text: "ADSON'S TEST:", bold:true, highlight:true },
{ text: "+ve in cervical rib: radial pulse obliterated on deep inspiration + turning head", indent:true },
{ text: "ALLEN'S TEST:", bold:true, highlight:true },
{ text: "For radial/ulnar artery patency", indent:true },
{ text: "CAPILLARY RETURN:", bold:true, highlight:true },
{ text: "Blanch nail bed — return >2 sec = abnormal", indent:true },
{ text: "AUSCULTATION:", bold:true, highlight:true },
{ text: "Bruits over aorta, iliacs, femorals — turbulence at stenosis", indent:true },
];
bulletSlide(s, special, 9.2, 1.6, 3.6, 5.2, { fontSize:10.5 });
}
// ─── SLIDE 8: BUERGER'S ANGLE & BUERGER'S DISEASE ────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Buerger's Test & Buerger's Disease", "S. Das 13e | Bailey & Love 28e | Schwartz 11e");
// Left: Buerger's test
s.addShape(pres.ShapeType.rect, { x:0.3, y:1.1, w:6.1, h:5.9, fill:{ color:C.midBg }, line:{ color:C.accent, pt:1.5 } });
s.addText("BUERGER'S TEST (Angle of Ischaemia)", {
x:0.5, y:1.15, w:5.7, h:0.4, fontSize:13, bold:true, color:C.gold, fontFace:"Calibri"
});
const buergerTest = [
{ text: "ELEVATION PHASE:", bold:true, highlight:true },
{ text: "Patient supine, leg raised slowly", indent:true },
{ text: "Angle at which limb becomes pale = Buerger's angle", indent:true },
{ text: "Normal: pallor never occurs up to 90°", indent:true },
{ text: "Mild ischaemia: pallor at 45–60°", indent:true },
{ text: "Severe ischaemia: pallor at <20° (critical ischaemia)", indent:true },
{ text: "DEPENDENCY PHASE:", bold:true, highlight:true },
{ text: "After elevation, leg hung down", indent:true },
{ text: "Normal: veins refill in <5 seconds", indent:true },
{ text: "Ischaemic: guttered veins refill in >15 sec; reactive hyperaemia (brick-red colour) — pathognomonic", indent:true },
{ text: "SIGNIFICANCE:", bold:true, highlight:true },
{ text: "Buerger's angle <15° = critical ischaemia = urgent intervention", indent:true },
{ text: "Helps assess severity before ABI measurement", indent:true },
];
bulletSlide(s, buergerTest, 0.5, 1.6, 5.7, 5.2, { fontSize:11 });
// Right: Buerger's Disease
s.addShape(pres.ShapeType.rect, { x:6.9, y:1.1, w:6.1, h:5.9, fill:{ color:C.midBg }, line:{ color:C.gold, pt:1.5 } });
s.addText("BUERGER'S DISEASE (Thromboangiitis Obliterans)", {
x:7.1, y:1.15, w:5.7, h:0.4, fontSize:12.5, bold:true, color:C.gold, fontFace:"Calibri"
});
const buergersDisease = [
{ text: "DEFINITION:", bold:true, highlight:true },
{ text: "Non-atherosclerotic, segmental, inflammatory disease affecting small-medium arteries AND veins of upper & lower limbs", indent:true },
{ text: "EPIDEMIOLOGY:", bold:true, highlight:true },
{ text: "Young males (20–40 years), heavy smoker, no cardiovascular risk factors", indent:true },
{ text: "More common in Middle East, Southeast Asia, Indian subcontinent", indent:true },
{ text: "PATHOLOGY:", bold:true, highlight:true },
{ text: "Inflammatory occlusive thrombus — highly cellular (unlike atherosclerosis)", indent:true },
{ text: "Both arteries AND veins involved (migratory thrombophlebitis)", indent:true },
{ text: "CLINICAL FEATURES:", bold:true, highlight:true },
{ text: "Distal claudication: arch of foot, forearm", indent:true },
{ text: "Raynaud's phenomenon; Superficial thrombophlebitis", indent:true },
{ text: "Rest pain → digital gangrene → amputation", indent:true },
{ text: "TREATMENT:", bold:true, highlight:true },
{ text: "Complete smoking cessation (absolute must) — arrests disease", indent:true },
{ text: "Prostaglandins (PGE1/Iloprost) for severe ischaemia", indent:true },
{ text: "Sympathectomy: useful in early vasospasm stage", indent:true },
{ text: "Amputation if gangrene — at digital level if possible", indent:true },
];
bulletSlide(s, buergersDisease, 7.1, 1.6, 5.7, 5.2, { fontSize:11 });
}
// ─── SLIDE 9: INVESTIGATIONS ─────────────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Investigations", "S. Das 13e | Bailey & Love 28e | Sabiston");
s.addText("ANKLE-BRACHIAL PRESSURE INDEX (ABPI / ABI) — THE MOST IMPORTANT BEDSIDE TEST", {
x:0.3, y:1.0, w:12.7, h:0.38,
fontSize:11.5, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:1
});
const abiRows = [
["ABI Value", "Interpretation", "Clinical Correlation"],
["> 1.3", "Non-compressible vessels", "DM / CKD — vessels calcified (falsely high)"],
["0.9 – 1.3", "Normal", "No significant PAD"],
["0.7 – 0.9", "Mild PAD", "Claudication at >200m (Fontaine IIa)"],
["0.5 – 0.7", "Moderate PAD", "Claudication at <200m (Fontaine IIb)"],
["0.3 – 0.5", "Severe PAD", "Rest pain present (Fontaine III)"],
["< 0.3", "Critical ischaemia", "Ulceration / gangrene (Fontaine IV)"],
];
s.addTable(abiRows.map((row, ri) => row.map((cell, ci) => ({
text: cell,
options: {
bold: ri === 0 || ri >= 5,
color: ri === 0 ? C.white : (ri >= 5 ? C.gold : C.lightText),
fill: ri === 0 ? C.tableHdr : (ri % 2 === 0 ? C.tableBand : C.midBg),
fontSize: ri === 0 ? 11.5 : 11,
fontFace:"Calibri",
align: ci === 0 ? "center" : "left"
}
}))), { x:0.3, y:1.45, w:12.7, colW:[2.0, 3.0, 7.7], rowH:0.42, border:{ type:"solid", color:"334466", pt:0.5 } });
// Other investigations
s.addText("OTHER KEY INVESTIGATIONS", {
x:0.3, y:4.55, w:12.7, h:0.38,
fontSize:11.5, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
s.addTable([
["Investigation", "Findings / Purpose"],
["Duplex Ultrasound (DUS)", "First-line imaging: stenosis location, velocity, peak systolic velocity ratio >2 = significant stenosis"],
["CT Angiography (CTA)", "Gold standard non-invasive — full arterial road map for surgical planning; rapid, widely available"],
["MR Angiography (MRA)", "No radiation; useful in renal impairment; overestimates stenosis"],
["Digital Subtraction Angiography (DSA)", "Gold standard invasive; done before endovascular treatment; gives therapeutic option simultaneously"],
["Toe Brachial Index (TBI)", "Useful in DM (ABI unreliable); <0.7 = abnormal; <0.15 = critical ischaemia"],
["Bloods: FBC, RFT, LFT, lipids, HbA1c, coag", "Assess comorbidities, renal function before contrast; surgical fitness"],
["ECG + Echo + Cardiac stress test", "Perioperative cardiac risk assessment — essential before major vascular surgery"],
].map((row, ri) => row.map((cell) => ({
text: cell,
options: {
bold: ri === 0,
color: ri === 0 ? C.white : C.lightText,
fill: ri === 0 ? C.tableHdr : (ri % 2 === 0 ? C.tableBand : C.midBg),
fontSize: ri === 0 ? 11 : 10.5,
fontFace:"Calibri"
}
}))), { x:0.3, y:5.0, w:12.7, colW:[4.0, 8.7], rowH:0.35, border:{ type:"solid", color:"334466", pt:0.5 } });
}
// ─── SLIDE 10: ACUTE LIMB ISCHAEMIA ──────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Acute Limb Ischaemia", "Bailey & Love 28e | S. Das 13e | Schwartz 11e");
// 6 Ps
s.addShape(pres.ShapeType.rect, { x:0.3, y:1.1, w:12.7, h:1.6, fill:{ color:C.midBg }, line:{ color:C.accent, pt:2 } });
s.addText("THE 6 Ps OF ACUTE LIMB ISCHAEMIA", {
x:0.5, y:1.15, w:12.3, h:0.38, fontSize:13, bold:true, color:C.accent, fontFace:"Calibri", charSpacing:2
});
const ps = ["Pain", "Pallor", "Pulselessness", "Paraesthesia", "Paralysis", "Perishing with cold"];
ps.forEach((p, i) => {
const x = 0.5 + i * 2.1;
s.addShape(pres.ShapeType.rect, { x, y:1.6, w:1.9, h:0.9, fill:{ color:C.accentSoft }, line:{ color:C.gold, pt:1 } });
s.addText(p, { x, y:1.6, w:1.9, h:0.9, fontSize:11.5, bold:true, color:C.white, fontFace:"Calibri", align:"center", valign:"middle" });
});
s.addText("Neurological symptoms (paraesthesia/paralysis) indicate irreversible ischaemia is imminent — surgical emergency", {
x:0.3, y:2.62, w:12.7, h:0.38, fontSize:11, color:C.gold, italic:true, fontFace:"Calibri"
});
// Embolus vs Thrombosis table
s.addText("EMBOLUS vs. THROMBOSIS — KEY DISTINCTION (Viva Favourite!)", {
x:0.3, y:3.1, w:12.7, h:0.38, fontSize:12, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
s.addTable([
["Feature", "Arterial Embolism", "Acute-on-Chronic Thrombosis"],
["Onset", "Sudden, acute (<1 hr)", "Gradual (hours-days)"],
["Prior symptoms", "None — no claudication", "H/o claudication present"],
["Contralateral limb", "Normal pulses", "Absent/reduced pulses"],
["Cardiac history", "AF, MI, Valvular disease", "Atherosclerosis risk factors"],
["Limb viability", "Severely threatened (no collaterals)", "Less severe (collaterals present)"],
["Angiography", "Sharp cut-off, no collaterals", "Irregular, collaterals present"],
["Treatment", "Embolectomy (Fogarty catheter)", "Thrombolysis / bypass first"],
].map((row, ri) => row.map((cell, ci) => ({
text: cell,
options: {
bold: ri === 0 || ci === 0,
color: ri === 0 ? C.white : (ci === 0 ? C.gold : C.lightText),
fill: ri === 0 ? C.tableHdr : (ci === 0 ? "1A2F4F" : (ri % 2 === 0 ? C.tableBand : C.midBg)),
fontSize: ri === 0 ? 11.5 : 11,
fontFace:"Calibri"
}
}))), { x:0.3, y:3.55, w:12.7, colW:[2.8, 5.0, 4.9], rowH:0.38, border:{ type:"solid", color:"334466", pt:0.5 } });
// Rutherford ALI
s.addShape(pres.ShapeType.rect, { x:0.3, y:6.65, w:12.7, h:0.6, fill:{ color:"1A2F4F" }, line:{ color:C.accent, pt:1 } });
s.addText([
{ text: "RUTHERFORD CLASSIFICATION of ALI: ", options:{ bold:true, color:C.gold } },
{ text: "Class I — Viable (no immediate threat) | Class IIa — Marginally threatened | Class IIb — Immediately threatened (motor loss) | Class III — Irreversible (major tissue loss inevitable) → primary amputation", options:{ color:C.lightText } }
], { x:0.5, y:6.68, w:12.3, h:0.55, fontSize:10.5, fontFace:"Calibri", valign:"middle" });
}
// ─── SLIDE 11: MANAGEMENT — MEDICAL / ENDOVASCULAR ───────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Management — Medical & Endovascular", "Sabiston | Schwartz 11e | Bailey & Love 28e");
// Medical Management
s.addShape(pres.ShapeType.rect, { x:0.3, y:1.1, w:5.9, h:5.9, fill:{ color:C.midBg }, line:{ color:C.accent, pt:1 } });
s.addText("MEDICAL MANAGEMENT (Claudication)", {
x:0.5, y:1.15, w:5.5, h:0.4, fontSize:12, bold:true, color:C.accent, fontFace:"Calibri"
});
const medical = [
{ text: "RISK FACTOR MODIFICATION:", bold:true, highlight:true },
{ text: "Smoking cessation — most important single intervention", indent:true },
{ text: "Tight glycaemic control (HbA1c <7%)", indent:true },
{ text: "Blood pressure control (<130/80 mmHg)", indent:true },
{ text: "Statins — target LDL <70 mg/dL; pleiotropic effects", indent:true },
{ text: "ANTIPLATELET THERAPY:", bold:true, highlight:true },
{ text: "Aspirin 75–150 mg/day OR Clopidogrel 75 mg/day", indent:true },
{ text: "Dual antiplatelet post-intervention", indent:true },
{ text: "EXERCISE REHABILITATION:", bold:true, highlight:true },
{ text: "Supervised walking programme — 30–60 min, 3x/week", indent:true },
{ text: "Increases claudication distance by 100–150%", indent:true },
{ text: "PHARMACOLOGICAL:", bold:true, highlight:true },
{ text: "Cilostazol (phosphodiesterase inhibitor) — improves claudication distance", indent:true },
{ text: "Naftidrofuryl oxalate — alternative to cilostazol", indent:true },
{ text: "Prostaglandins (PGE1/Iloprost) — critical ischaemia", indent:true },
{ text: "Anticoagulation (warfarin / LMWH) post-bypass", indent:true },
];
bulletSlide(s, medical, 0.5, 1.6, 5.5, 5.2, { fontSize:10.5 });
// Endovascular
s.addShape(pres.ShapeType.rect, { x:6.6, y:1.1, w:6.4, h:5.9, fill:{ color:C.midBg }, line:{ color:C.gold, pt:1 } });
s.addText("ENDOVASCULAR TREATMENT", {
x:6.8, y:1.15, w:6.0, h:0.4, fontSize:12, bold:true, color:C.gold, fontFace:"Calibri"
});
const endo = [
{ text: "INDICATIONS:", bold:true, highlight:true },
{ text: "Lifestyle-limiting claudication + failed conservative", indent:true },
{ text: "Critical limb ischaemia (rest pain/ulceration)", indent:true },
{ text: "TASC A/B lesions — endovascular preferred", indent:true },
{ text: "PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA):", bold:true, highlight:true },
{ text: "Balloon dilatation of stenosis or short occlusion", indent:true },
{ text: "Best results: iliac > femoral > popliteal", indent:true },
{ text: "STENTING:", bold:true, highlight:true },
{ text: "Balloon-expandable (iliac) or self-expanding (SFA)", indent:true },
{ text: "Drug-eluting stents / stent grafts — reduce restenosis", indent:true },
{ text: "THROMBOLYSIS:", bold:true, highlight:true },
{ text: "Catheter-directed tPA for acute thrombus (<14 days)", indent:true },
{ text: "Uncovers underlying stenosis for definitive treatment", indent:true },
{ text: "CI: recent stroke, active bleed, recent surgery", indent:true },
{ text: "NEWER TECHNIQUES:", bold:true, highlight:true },
{ text: "Atherectomy (rotational/laser) | Drug-coated balloons", indent:true },
{ text: "EVAR for aneurysmal disease", indent:true },
];
bulletSlide(s, endo, 6.8, 1.6, 6.0, 5.2, { fontSize:10.5 });
}
// ─── SLIDE 12: SURGICAL MANAGEMENT ───────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Surgical Management", "Bailey & Love 28e | Schwartz 11e | S. Das 13e");
// Reconstructive procedures
s.addText("RECONSTRUCTIVE / BYPASS PROCEDURES", {
x:0.3, y:1.0, w:12.7, h:0.38, fontSize:12, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:2
});
s.addTable([
["Procedure", "Indication / Level", "Conduit / Technique"],
["Aorto-bifemoral bypass", "Aorto-iliac occlusion (Leriche)", "Dacron bifurcation graft — gold standard"],
["Ilio-femoral bypass", "Unilateral iliac occlusion", "PTFE / Dacron graft"],
["Femoro-popliteal bypass", "SFA occlusion — above / below knee", "Long saphenous vein (preferred) or PTFE"],
["Femoro-distal bypass", "Tibio-peroneal disease (CLI)", "Reversed saphenous vein — best patency"],
["Embolectomy (Fogarty)", "Acute limb ischaemia — embolus", "Fogarty balloon catheter via femoral artery"],
["Endarterectomy", "Short localised disease — iliac / CFA", "Remove intima + plaque, patch angioplasty"],
["Extra-anatomic bypass", "Bilateral iliac disease, unfit patient", "Axillo-femoral / femoro-femoral crossover"],
].map((row, ri) => row.map((cell, ci) => ({
text: cell,
options: {
bold: ri === 0,
color: ri === 0 ? C.white : (ci === 0 ? C.gold : C.lightText),
fill: ri === 0 ? C.tableHdr : (ri % 2 === 0 ? C.tableBand : C.midBg),
fontSize: ri === 0 ? 11.5 : 11,
fontFace:"Calibri"
}
}))), { x:0.3, y:1.45, w:12.7, colW:[3.5, 4.5, 4.7], rowH:0.42, border:{ type:"solid", color:"334466", pt:0.5 } });
// Amputation
s.addShape(pres.ShapeType.rect, { x:0.3, y:4.6, w:6.1, h:2.65, fill:{ color:C.midBg }, line:{ color:C.accent, pt:1.5 } });
s.addText("AMPUTATION", {
x:0.5, y:4.65, w:5.7, h:0.38, fontSize:12, bold:true, color:C.accent, fontFace:"Calibri"
});
const amputation = [
{ text: "INDICATIONS: non-salvageable limb, failed bypass, irreversible ischaemia, extensive wet gangrene" },
{ text: "LEVELS: digit → ray → transmetatarsal → Syme's → below-knee (BKA) → above-knee (AKA)" },
{ text: "BKA preferred over AKA: better prosthetic rehabilitation; energy expenditure lower" },
{ text: "AKA if: flexion contracture, failed BKA, knee joint involvement" },
{ text: "Rule: amputate through viable tissue — healing depends on adequate blood supply" },
];
bulletSlide(s, amputation, 0.5, 5.1, 5.7, 2.0, { fontSize:11 });
// Sympathectomy
s.addShape(pres.ShapeType.rect, { x:6.9, y:4.6, w:6.1, h:2.65, fill:{ color:C.midBg }, line:{ color:C.gold, pt:1.5 } });
s.addText("SYMPATHECTOMY", {
x:7.1, y:4.65, w:5.7, h:0.38, fontSize:12, bold:true, color:C.gold, fontFace:"Calibri"
});
const sympath = [
{ text: "LUMBAR SYMPATHECTOMY: best for inoperable distal disease, rest pain, Buerger's disease (early), Raynaud's" },
{ text: "Mechanism: removes vasospasm, improves skin/subcutaneous circulation; NOT useful for muscle claudication" },
{ text: "METHODS: surgical (L2–L4 ganglia) or chemical (phenol injection) or laparoscopic" },
{ text: "CERVICAL sympathectomy: for upper limb vasospasm / hyperhidrosis" },
{ text: "Contraindicated in: fixed organic stenosis with no vasospasm component" },
];
bulletSlide(s, sympath, 7.1, 5.1, 5.7, 2.0, { fontSize:11 });
}
// ─── SLIDE 13: GANGRENE ───────────────────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Gangrene — Types, Differences & Management", "S. Das 13e | Bailey & Love 28e");
s.addTable([
["Feature", "Dry Gangrene", "Wet Gangrene", "Gas Gangrene"],
["Definition", "Coagulative necrosis — arterial ischaemia without infection", "Ischaemia + superimposed bacterial infection", "Clostridium infection with gas production"],
["Mechanism", "Mummification — tissue dries and shrivels", "Putrefaction — liquefaction necrosis", "Toxin-mediated myonecrosis"],
["Smell", "Absent (no bacteria)", "Foul-smelling putrefaction", "Sweet, mousy odour"],
["Colour", "Black, mummified, shrunken", "Black/green, swollen, moist", "Bronze/grey, crepitus on palpation"],
["Demarcation", "Clear line of demarcation (wait)", "Spreading — no clear demarcation", "Rapid spreading — no demarcation"],
["Systemic signs", "Minimal — patient relatively well", "Severe: fever, toxaemia, septic shock", "Severe toxaemia — rapidly fatal if untreated"],
["Treatment", "Conservative → elective amputation", "Emergency debridement + IV antibiotics + amputation", "Hyperbaric O2 + wide excision + penicillin"],
].map((row, ri) => row.map((cell, ci) => ({
text: cell,
options: {
bold: ri === 0 || ci === 0,
color: ri === 0 ? C.white : (ci === 0 ? C.gold : C.lightText),
fill: ri === 0 ? C.tableHdr : (ci === 0 ? "1A2F4F" : (ri % 2 === 0 ? C.tableBand : C.midBg)),
fontSize: ri === 0 ? 11 : 10.5,
fontFace:"Calibri"
}
}))), { x:0.3, y:1.1, w:12.7, colW:[2.4, 3.3, 3.7, 3.3], rowH:0.5, border:{ type:"solid", color:"334466", pt:0.5 } });
// Types of ulcers
s.addText("ARTERIAL vs. VENOUS vs. NEUROPATHIC ULCER — KEY COMPARISON", {
x:0.3, y:5.4, w:12.7, h:0.38, fontSize:12, bold:true, color:C.gold, fontFace:"Calibri", charSpacing:1
});
s.addTable([
["Feature", "Arterial Ulcer", "Venous Ulcer", "Neuropathic Ulcer"],
["Site", "Tips of toes, heels, malleoli (pressure)", "Gaiter area (above medial malleolus)", "Pressure points: heel, metatarsal heads"],
["Pain", "Very painful (ischaemic)", "Mild to moderate", "Painless (anaesthetic)"],
["Edge", "Punched-out, well-defined", "Sloping, irregular", "Punched-out, callus rim"],
["Base", "Pale, necrotic, no granulation", "Pink granulation tissue", "Deep, may reach bone"],
["Surrounding", "Cold, pallor, hairless skin", "Pigmentation, lipodermatosclerosis", "Warm, deformed foot (Charcot)"],
].map((row, ri) => row.map((cell, ci) => ({
text: cell,
options: {
bold: ri === 0 || ci === 0,
color: ri === 0 ? C.white : (ci === 0 ? C.gold : C.lightText),
fill: ri === 0 ? C.tableHdr : (ci === 0 ? "1A2F4F" : (ri % 2 === 0 ? C.tableBand : C.midBg)),
fontSize: ri === 0 ? 11 : 10.5,
fontFace:"Calibri"
}
}))), { x:0.3, y:5.85, w:12.7, colW:[2.1, 3.5, 3.7, 3.4], rowH:0.34, border:{ type:"solid", color:"334466", pt:0.5 } });
}
// ─── SLIDE 14: RAYNAUD'S + THORACIC OUTLET ────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Raynaud's Phenomenon & Thoracic Outlet Syndrome", "Bailey & Love 28e | S. Das 13e");
// Raynaud's
s.addShape(pres.ShapeType.rect, { x:0.3, y:1.1, w:6.1, h:5.9, fill:{ color:C.midBg }, line:{ color:C.accent, pt:1 } });
s.addText("RAYNAUD'S PHENOMENON", {
x:0.5, y:1.15, w:5.7, h:0.4, fontSize:13, bold:true, color:C.gold, fontFace:"Calibri"
});
const raynaud = [
{ text: "DEFINITION: Episodic digital vasospasm triggered by cold/stress — triphasic colour change" },
{ text: "TRIPHASIC COLOUR CHANGE:", bold:true, highlight:true },
{ text: "WHITE (pallor): arterial vasospasm → digital ischaemia", indent:true },
{ text: "BLUE (cyanosis): venous stasis, slow flow, deoxygenation", indent:true },
{ text: "RED (rubor): reactive hyperaemia on rewarming", indent:true },
{ text: "RAYNAUD'S DISEASE (Primary):", bold:true, highlight:true },
{ text: "Idiopathic; young women; bilateral; no tissue loss; benign", indent:true },
{ text: "RAYNAUD'S SYNDROME (Secondary):", bold:true, highlight:true },
{ text: "Associated with: SLE, RA, scleroderma, CREST syndrome, Buerger's disease, vibration white finger, cervical rib", indent:true },
{ text: "TREATMENT:", bold:true, highlight:true },
{ text: "Avoid cold; heated gloves; stop smoking", indent:true },
{ text: "CCBs (Nifedipine) — first line drug", indent:true },
{ text: "Prostaglandins (Iloprost) — severe cases", indent:true },
{ text: "Sympathectomy: cervical (hands), lumbar (feet) — short-lived benefit", indent:true },
{ text: "Treat underlying cause in secondary disease", indent:true },
];
bulletSlide(s, raynaud, 0.5, 1.6, 5.7, 5.2, { fontSize:11 });
// TOS + Cervical Rib
s.addShape(pres.ShapeType.rect, { x:6.9, y:1.1, w:6.1, h:5.9, fill:{ color:C.midBg }, line:{ color:C.gold, pt:1 } });
s.addText("THORACIC OUTLET SYNDROME & CERVICAL RIB", {
x:7.1, y:1.15, w:5.7, h:0.4, fontSize:12, bold:true, color:C.gold, fontFace:"Calibri"
});
const tos = [
{ text: "CERVICAL RIB:", bold:true, highlight:true },
{ text: "Accessory rib arising from C7 vertebra", indent:true },
{ text: "Compresses subclavian artery / brachial plexus", indent:true },
{ text: "ADSON'S TEST:", bold:true, highlight:true },
{ text: "Deep inspiration + head rotation to affected side → radial pulse obliterated", indent:true },
{ text: "CLINICAL FEATURES:", bold:true, highlight:true },
{ text: "Upper limb claudication on exertion", indent:true },
{ text: "Neurological: C8/T1 distribution — medial arm/hand", indent:true },
{ text: "Wasting of thenar / hypothenar muscles", indent:true },
{ text: "Subclavian artery: post-stenotic dilation → thrombus → distal embolism", indent:true },
{ text: "Arterial: pallor, coldness, Raynaud's, digital ischaemia", indent:true },
{ text: "INVESTIGATIONS:", bold:true, highlight:true },
{ text: "CXR / Cervical spine X-ray — cervical rib visible", indent:true },
{ text: "Duplex / Angiography — subclavian compression", indent:true },
{ text: "TREATMENT:", bold:true, highlight:true },
{ text: "Physiotherapy (minor cases) → surgical excision of rib + scalenectomy", indent:true },
{ text: "Subclavian reconstruction if post-stenotic aneurysm", indent:true },
];
bulletSlide(s, tos, 7.1, 1.6, 5.7, 5.2, { fontSize:11 });
}
// ─── SLIDE 15: VIVA QUESTIONS ─────────────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "High-Yield Viva Questions & Answers", "PG Surgery Examination Prep");
const vivas = [
{ q: "Q1. What is critical limb ischaemia?", a: "Rest pain >2 weeks + ABI <0.5 OR ankle pressure <50 mmHg OR toe pressure <30 mmHg OR tissue loss (ulcer/gangrene) — requires urgent revascularisation" },
{ q: "Q2. What is the Fontaine classification?", a: "Stage I: Asymptomatic | IIa: Claudication >200m | IIb: <200m | III: Rest pain | IV: Ulcer/gangrene" },
{ q: "Q3. How do you differentiate embolism from thrombosis?", a: "Embolism: sudden, no prior claudication, normal contralateral limb, cardiac source (AF/MI), sharp angio cut-off. Thrombosis: gradual, h/o claudication, bilateral disease, collaterals on angio" },
{ q: "Q4. What is Leriche syndrome?", a: "Aorto-iliac occlusion: triad of bilateral hip/thigh/buttock claudication + absent femoral pulses + impotence in males" },
{ q: "Q5. Best conduit for femoropopliteal bypass?", a: "Long saphenous vein (reversed or in-situ) — best patency. PTFE acceptable above-knee when vein unavailable" },
{ q: "Q6. When is sympathectomy indicated?", a: "Inoperable distal PVD, rest pain, Buerger's disease (vasospasm phase), Raynaud's, hyperhidrosis. Not useful for claudication (muscle ischaemia)" },
{ q: "Q7. ABI falsely high in diabetes — why?", a: "Medial calcification makes tibial arteries non-compressible. Use toe-brachial index (TBI) instead — <0.7 abnormal" },
{ q: "Q8. Fogarty catheter — describe the procedure", a: "Groin incision, expose CFA; transverse arteriotomy; catheter passed distal & proximal to clot, balloon inflated, withdrawn — clot extracted; angiogram to confirm; heparin systemically" },
];
let yPos = 1.08;
vivas.forEach((item, i) => {
const row = Math.floor(i/2);
const col = i % 2;
const x = col === 0 ? 0.3 : 6.85;
const y = 1.08 + row * 1.52;
s.addShape(pres.ShapeType.rect, { x, y, w:6.15, h:1.42, fill:{ color:C.midBg }, line:{ color: i%2===0 ? C.accent : C.gold, pt:1 } });
s.addText([
{ text: item.q + "\n", options:{ bold:true, color:C.gold, fontSize:10.5 } },
{ text: item.a, options:{ color:C.lightText, fontSize:10 } }
], { x: x+0.15, y: y+0.05, w:5.85, h:1.3, fontFace:"Calibri", valign:"top" });
});
}
// ─── SLIDE 16: MORE VIVA QUESTIONS ────────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "High-Yield Viva Questions — Continued", "PG Surgery Examination Prep");
const vivas2 = [
{ q: "Q9. Features of Buerger's disease vs. atherosclerosis", a: "Buerger's: young (20-40y), male, heavy smoker, no CV risk factors, involves distal small vessels AND veins, migratory thrombophlebitis, no calcium on angio. Atherosclerosis: older, proximal disease, CV risk factors" },
{ q: "Q10. What is the ankle-brachial pressure index and how to measure?", a: "ABPI = ankle systolic BP ÷ brachial systolic BP. Measured with hand-held Doppler. Normal >0.9. <0.5 = severe. >1.3 = calcified vessels (DM). Resting + post-exercise (treadmill) increases sensitivity" },
{ q: "Q11. What investigations before vascular surgery?", a: "FBC, U&E, LFT, coag screen, HbA1c, lipid profile, ECG, echo, cardiac stress test (if high risk), CXR, duplex USS, CT angiography, chest x-ray, PFTs if indicated" },
{ q: "Q12. Indications for amputation in PVD?", a: "Irreversible ischaemia (Rutherford III), failed/not feasible revascularisation, extensive tissue loss/wet gangrene, sepsis threatening life, intractable rest pain with no option, Buerger's with digital gangrene" },
{ q: "Q13. Types of bypass graft materials?", a: "Autologous vein (LSV — gold standard), PTFE (above-knee acceptable), Dacron (aortic/iliac), Cryopreserved vein, Human umbilical vein. Vein > PTFE for below-knee and all infra-inguinal bypasses" },
{ q: "Q14. Complications of vascular surgery?", a: "General: MI, stroke, renal failure, DVT/PE. Local: graft thrombosis, infection, anastomotic leak, false aneurysm, lymphocele, nerve injury, reperfusion injury, compartment syndrome post-embolectomy" },
{ q: "Q15. What is reperfusion injury?", a: "After revascularisation, restoration of blood flow → xanthine oxidase-generated free radicals, inflammatory mediators → cell death, oedema, compartment syndrome, myoglobinuria → AKI. Managed with fasciotomy, hydration, bicarbonate" },
{ q: "Q16. What is Leriche's symptom complex vs Fontaine staging?", a: "Leriche: clinical syndrome of aorto-iliac occlusion (the 3 features). Fontaine: grading severity of any chronic lower limb ischaemia I–IV. They address different aspects of PVD" },
];
vivas2.forEach((item, i) => {
const col = i % 2;
const row = Math.floor(i/2);
const x = col === 0 ? 0.3 : 6.85;
const y = 1.08 + row * 1.52;
s.addShape(pres.ShapeType.rect, { x, y, w:6.15, h:1.42, fill:{ color:C.midBg }, line:{ color: col===0 ? C.accent : C.gold, pt:1 } });
s.addText([
{ text: item.q + "\n", options:{ bold:true, color:C.gold, fontSize:10.5 } },
{ text: item.a, options:{ color:C.lightText, fontSize:10 } }
], { x: x+0.15, y: y+0.05, w:5.85, h:1.3, fontFace:"Calibri", valign:"top" });
});
}
// ─── SLIDE 17: SUMMARY / KEY POINTS ──────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
addSlideHeader(s, "Summary — Key Take-Home Points", "For the Examiner's Corner");
const keyPoints = [
{ text: "PVD most commonly = atherosclerosis; Buerger's = young male smoker with distal + venous involvement", bold:true, highlight:true },
{ text: "Fontaine I→IV: asymptomatic → claudication → rest pain → gangrene/ulcer (correlate with ABI values)" },
{ text: "6 Ps of ALI: Pain, Pallor, Pulselessness, Paraesthesia, Paralysis, Perishing cold — paralysis = emergency" },
{ text: "ABI: <0.9 = PAD; <0.5 = severe; >1.3 = calcified (DM) — use TBI in diabetes" },
{ text: "Embolism: acute, cardiac source, sharp cut-off, no collaterals → Fogarty embolectomy" },
{ text: "Thrombosis: subacute, atherosclerosis background, collaterals → thrombolysis / bypass" },
{ text: "Gold standard bypass conduit = long saphenous vein; Dacron for aortic work; PTFE above-knee" },
{ text: "Leriche syndrome: aorto-iliac occlusion → bilateral claudication + absent femorals + impotence" },
{ text: "Buerger's angle <15° = critical ischaemia; Dependency test: reactive hyperaemia >15s = significant" },
{ text: "Sympathectomy: useful for vasospasm/distal disease — NOT muscle claudication" },
{ text: "Dry gangrene: await demarcation → elective amputation | Wet gangrene: emergency debridement + amputation" },
{ text: "Pre-op work-up: cardiac assessment mandatory — PVD + CAD frequently coexist (same aetiology)" },
];
bulletSlide(s, keyPoints, 0.5, 1.15, 12.3, 6.0, { fontSize:12 });
}
// ─── SLIDE 18: REFERENCES ─────────────────────────────────────────────────────
{
const s = pres.addSlide();
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:7.5, fill:{ color:C.darkBg } });
s.addShape(pres.ShapeType.rect, { x:0, y:0, w:13.3, h:0.85, fill:{ color:C.accentSoft } });
s.addText("REFERENCES & SOURCES", {
x:0.25, y:0.05, w:12.8, h:0.75,
fontSize:22, bold:true, color:C.white, fontFace:"Calibri", align:"left", valign:"middle", margin:0
});
s.addShape(pres.ShapeType.rect, { x:0, y:7.25, w:13.3, h:0.25, fill:{ color:C.accentSoft } });
const refs = [
"1. Norman S. Williams, Christopher J.K. Bulstrode, P. Ronan O'Connell. Bailey & Love's Short Practice of Surgery, 28th Edition. CRC Press, 2023. — Chapter 61: Peripheral Vascular Disease",
"2. S. Das. A Manual on Clinical Surgery, 13th Edition. — Chapter 6: Peripheral Vascular Disease, Pg. 88–105",
"3. F. Charles Brunicardi et al. Schwartz's Principles of Surgery, 11th Edition. McGraw-Hill, 2019. — Chapter 23: Arterial Disease",
"4. Courtney M. Townsend et al. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice, 21st Edition. Elsevier, 2022.",
"5. John L. Cameron, Andrew M. Cameron. Current Surgical Therapy, 14th Edition. Elsevier, 2023.",
"6. Mulholland & Greenfield's Surgery: Scientific Principles and Practice, 7th Edition. Wolters Kluwer, 2022.",
"7. Kumar V, Abbas AK, Aster JC. Robbins & Cotran Pathologic Basis of Disease, 10th Edition. Chapter 11: Blood Vessels",
"8. Norgren L, Hiatt WR, Dormandy JA et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75.",
];
refs.forEach((ref, i) => {
s.addText(ref, {
x:0.5, y: 1.1 + i * 0.75,
w:12.3, h:0.65,
fontSize:11, color: i % 2 === 0 ? C.lightText : C.subText,
fontFace:"Calibri", valign:"top"
});
});
}
// ─── WRITE FILE ───────────────────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/pvd-presentation/PVD_Case_Presentation_PG_Surgery.pptx" })
.then(() => console.log("PPT created successfully!"))
.catch(e => console.error("Error:", e));
Running Command
cd /home/daytona/workspace/pvd-presentation && node pvd_ppt.js 2>&1
Running Command
ls -lh /home/daytona/workspace/pvd-presentation/PVD_Case_Presentation_PG_Surgery.pptx
Your presentation is ready! Download it here:
PVD Case Presentation PG Surgery
Presentation · PPTX
What's Inside (18 Slides)
The deck uses a deep navy + arterial red + gold palette designed for a surgical case presentation. Here's the full breakdown:
| Slide | Content |
|---|---|
| 1 | Title Slide — with all source books listed |
| 2 | Case Vignette — 58M, diabetic, smoker, claudication + rest pain + ulcer + gangrene (covers all 4 Fontaine stages in one case) |
| 3 | Definitions & Classification — Fontaine I–IV table with ABI values + TASC II overview |
| 4 | Aetiology & Risk Factors — all causes of PVD + risk factor table (modifiable/non-modifiable) |
| 5 | Pathophysiology — atherosclerosis step-by-step flow + haemodynamic & tissue consequences |
| 6 | Clinical Features / Symptoms — Fontaine-correlated symptom table + Leriche syndrome |
| 7 | Clinical Examination — Inspection / Palpation / Special Tests (Buerger's, Adson's, Allen's) |
| 8 | Buerger's Test + Buerger's Disease — both in one slide; Buerger's angle interpretation |
| 9 | Investigations — ABI interpretation table + Duplex, CTA, MRA, DSA, TBI, bloods |
| 10 | Acute Limb Ischaemia — 6 Ps + Embolism vs. Thrombosis comparison + Rutherford ALI |
| 11 | Medical & Endovascular Management — risk modification + antiplatelet + PTA + stenting + thrombolysis |
| 12 | Surgical Management — bypass procedures table + amputation levels + sympathectomy |
| 13 | Gangrene — Dry vs. Wet vs. Gas gangrene + Arterial vs. Venous vs. Neuropathic ulcer |
| 14 | Raynaud's Phenomenon + TOS / Cervical Rib — triphasic colour change + Adson's test |
| 15–16 | Viva Q&A (16 questions) — all classic PG surgery viva topics answered concisely |
| 17 | Summary / Key Take-home Points |
| 18 | References — Bailey & Love, S. Das, Schwartz, Sabiston, Current Surgical Therapy, TASC II |
image.jpg
Detailed answers according to the weightage from standard textbooks
Reading File
This is a 5-question, 100-mark PG General Surgery prelims paper. Let me search all topics in parallel from the library.
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
I now have sufficient content from the library. Let me compile the comprehensive answers for all 5 questions now.---
DEPARTMENT OF SURGERY, MPSGMC JAMNAGAR
M.S. Branch-1 (General Surgery) Prelims — 24-08-2025
Detailed Model Answers
Q.1 — Lymphovascular Anatomy of Stomach + Aetiopathology, Clinical Features, Stages and Management of Carcinoma Stomach (20 Marks)
PART A: LYMPHO-VASCULAR ANATOMY OF THE STOMACH
Arterial Supply (Bailey & Love 28e, Chapter 67)
The stomach has a rich dual-arcade blood supply along both curvatures:
| Artery | Origin | Supply |
|---|---|---|
| Left gastric (smallest/most important surgically) | Coeliac trunk | Lesser curvature upper portion |
| Right gastric | Hepatic artery | Lesser curvature lower portion |
| Right gastroepiploic | Gastroduodenal artery | Greater curvature right side |
| Left gastroepiploic | Splenic artery | Greater curvature left side |
| Short gastric vessels (vasa brevia) | Splenic artery (5-7 branches) | Fundus |
| Posterior gastric artery | Splenic artery | Posterior fundus / body |
The right and left gastric arteries form the lesser curvature arcade; right and left gastroepiploic arteries form the greater curvature arcade. This dual blood supply means the stomach tolerates extensive devascularisation - the basis of gastric tube formation for oesophageal replacement.
Venous Drainage
All gastric veins drain ultimately into the portal system:
- Left & right gastric veins → portal vein directly
- Right gastroepiploic → superior mesenteric vein
- Left gastroepiploic + short gastric veins → splenic vein
- The left gastric (coronary) vein is an important portosystemic communication in portal hypertension
Lymphatic Drainage — The Key to Staging and Surgery
The stomach's lymphatic drainage follows the arterial supply. The Japanese Research Society for Gastric Cancer (JRSGC) defines nodal stations N1–N16, grouped into tiers for D-level resection:
N1 nodes (perigastric — along curvatures):
- Station 1: Right paracardial nodes
- Station 2: Left paracardial nodes
- Station 3: Nodes along lesser curvature
- Station 4: Nodes along greater curvature
- Station 5: Suprapyloric nodes
- Station 6: Infrapyloric nodes
N2 nodes (along named vessels — 2nd tier):
- Station 7: Along left gastric artery
- Station 8: Along common hepatic artery
- Station 9: Along coeliac axis
- Station 10: At splenic hilum
- Station 11: Along splenic artery
N3 nodes (3rd tier — distant):
- Station 12: Hepatoduodenal ligament
- Station 13: Posterior to pancreas head
- Station 14: Root of mesentery
- Station 16: Para-aortic nodes
D1 resection = removal of N1 nodes; D2 resection = N1 + N2 (standard for curative intent in Japan). Transcoelomic spread can deposit in the pouch of Douglas (Blumer's shelf), Krukenberg tumour (ovary), Sister Mary Joseph nodule (umbilicus) and Virchow's node (left supraclavicular).
PART B: CARCINOMA OF THE STOMACH
Epidemiology
- Second most common cause of cancer death worldwide
- Incidence: Japan 70/100,000/yr; UK 15/100,000/yr; USA 10/100,000/yr
- Male:Female = 2:1; peak incidence 6th–7th decade
- Incidence is falling in the West (body and antrum); rising for proximal/GOJ cancers
Aetiology and Predisposing Factors (Bailey & Love 28e; Schwartz 11e)
Infective:
- H. pylori — single most important aetiological factor for distal stomach cancer; classified as Group 1 carcinogen by WHO; causes chronic gastritis → intestinal metaplasia → dysplasia → carcinoma (Correa's cascade)
- EBV infection (10% of cases)
Dietary:
- High nitrate diet, smoked/pickled foods, salted fish
- Deficiency of antioxidants (Vitamins C, E)
- High sodium intake
Pre-malignant conditions:
- Chronic atrophic gastritis (pernicious anaemia) — achlorhydria → bacterial overgrowth → nitrosamines
- Intestinal metaplasia (incomplete type III most risky)
- Gastric polyps — adenomatous >2 cm carry 40% risk
- Post-gastrectomy stomach (Billroth II) — bile reflux; after 15–20 years
- Menetrier's disease (giant hypertrophic gastritis)
- Gastric ulcer — debatable; not proven
Genetic:
- CDH1 (E-cadherin) mutation — hereditary diffuse gastric cancer (HDGC)
- Li-Fraumeni syndrome (TP53 mutation), Lynch syndrome (MSI)
- First-degree relatives have 2–3× increased risk
Pathology
Macroscopic (Borrmann's Classification):
- Type I: Polypoid / fungating
- Type II: Ulcerating with sharp margins
- Type III: Ulcerating with infiltrating margins
- Type IV: Diffuse infiltrating (Linitis plastica — leather bottle stomach)
- Types III and IV carry worst prognosis
Microscopic (Laurén Classification):
- Intestinal type: Well-differentiated; gland formation; arises in intestinal metaplasia; associated with H. pylori; distal stomach; better prognosis
- Diffuse type: Poorly differentiated; signet ring cells; no gland formation; infiltrates diffusely; associated with CDH1 mutation; proximal stomach; worse prognosis; seen in younger patients
Early Gastric Cancer (EGC): Defined as cancer confined to mucosa and submucosa (T1), regardless of nodal status. Japanese classification (Types I–III): protruding, superficial (elevated/flat/depressed), excavated. 5-year survival >90% in Japan.
Advanced Gastric Cancer: Involves muscularis propria or beyond (T2 onwards).
Routes of Spread:
- Direct extension — adjacent organs (liver, pancreas, transverse colon)
- Lymphatic — sequential nodal stations as above; Virchow's node
- Haematogenous — liver (most common), lungs, adrenals, bone
- Transcoelomic — peritoneal seeding, Krukenberg tumour (ovaries), Blumer's shelf (pouch of Douglas), Sister Mary Joseph nodule (umbilicus)
Clinical Features
Early (often silent):
- Epigastric discomfort/pain
- Anorexia (especially for meat)
- Early satiety
Late / Advanced:
- Weight loss (most common presenting symptom)
- Dysphagia (GOJ / cardia involvement)
- Vomiting (pyloric obstruction)
- Haematemesis, melaena
- Anaemia (iron deficiency)
- Palpable epigastric mass
- Jaundice (liver metastases / biliary obstruction)
- Ascites (peritoneal seeding)
Signs:
- Virchow's node (left supraclavicular — Troisier's sign)
- Sister Mary Joseph nodule (umbilical metastasis)
- Blumer's shelf on PR examination (pouch of Douglas deposit)
- Hepatomegaly, ascites
Investigations
Endoscopy: Upper GI endoscopy with multiple biopsies from ulcer edge and base — gold standard for diagnosis.
Histology: Minimum 6–8 biopsies; brush cytology adds sensitivity.
Staging:
- CT chest/abdomen/pelvis: assess T, N, M stages; vascular invasion
- Endoscopic ultrasound (EUS): best for T and N staging (especially T1–T2)
- Diagnostic laparoscopy: mandatory before radical surgery to exclude peritoneal disease (+ lavage cytology)
- PET-CT: metabolically active disease, occult metastases
- MRI: liver metastases
Bloods: FBC (anaemia), LFT, tumour markers (CEA, CA 19-9 — low sensitivity but useful for monitoring recurrence)
Staging (TNM 8th Edition — UICC)
| Stage | Criteria |
|---|---|
| T1a | Tumour in lamina propria / muscularis mucosae |
| T1b | Tumour invades submucosa |
| T2 | Invades muscularis propria |
| T3 | Invades subserosa (without visceral peritoneum) |
| T4a | Penetrates visceral peritoneum (serosa) |
| T4b | Invades adjacent structures |
| N1 | 1–2 regional LN |
| N2 | 3–6 regional LN |
| N3a | 7–15 regional LN |
| N3b | >15 regional LN |
| M0/M1 | No / Yes distant metastases |
Note: Tumours within 5 cm of GOJ extending into oesophagus are staged as oesophageal cancers (8th edition change).
Management
Curative Surgery:
- Total gastrectomy: For proximal, body, or large antral tumours; Roux-en-Y oesophagojejunostomy reconstruction.
- Subtotal (distal) gastrectomy: For antral/pyloric cancers; preserves proximal stomach; oncologically equivalent for distal tumours; Billroth II (gastrojejunostomy) or Roux-en-Y reconstruction.
- Lymph node dissection: D2 gastrectomy (includes N1 + N2 nodes up to station 11) is the standard for curative intent. D2 is now widely recommended; D1 for unfit patients; D3 is investigational.
- Resection margins: At least 5 cm proximal and distal margins (8 cm for diffuse type).
Minimally Invasive: Laparoscopic / robotic gastrectomy increasingly performed in high-volume centres; equivalent oncological outcomes for T1–T2.
Endoscopic Resection: Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) for selected EGC (T1a, <2 cm, well-differentiated, no ulceration, no LN involvement).
Perioperative Chemotherapy (FLOT regimen):
FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) — 4 cycles pre-op + 4 cycles post-op — current standard of care (FLOT4 trial). Previous standard was ECF/ECX (Cunningham — MAGIC trial). Improves R0 resection rate and overall survival.
Adjuvant Chemoradiotherapy: MacDonald regimen (5-FU + RT) — used in North America post-operatively.
Targeted Therapy:
- Trastuzumab (HER2 positive, ~15–20% cases) — added to cisplatin-based chemotherapy for HER2+ advanced disease (ToGA trial)
- Anti-PD-1 immunotherapy (Nivolumab, Pembrolizumab) — for MSI-H or PD-L1+ advanced disease
Palliative Surgery/Endoscopy:
- Bypass gastrojejunostomy for inoperable pyloric obstruction
- Endoscopic stenting (GOJ obstruction)
- Feeding jejunostomy / PEG
- Palliative chemotherapy — FLOT, DCF, XELOX regimens
- Palliative radiotherapy for bleeding or pain
Prognosis:
5-year survival: Stage IA = ~85%; Stage IIA = ~50%; Stage IIIA = ~20%; Stage IV = <5%. Japan has significantly better outcomes (>50% 5-year survival) due to screening.
Q.2 — Congenital Anomalies of Kidney + Aetiopathology, Clinical Features, Investigations and Treatment of PUJ Obstruction (20 Marks)
PART A: CONGENITAL ANOMALIES OF THE KIDNEY
Congenital anomalies of kidney and urinary tract (CAKUT) have an incidence of 1 in 500 live births and are the commonest cause of CKD in children. They are classified as follows:
1. Anomalies of Number
- Bilateral renal agenesis (Potter syndrome): Complete absence of kidneys; incompatible with life; associated with oligohydramnios, pulmonary hypoplasia, Potter's facies (flattened nose, low-set ears, limb deformities)
- Unilateral renal agenesis: 1 in 1000; contralateral kidney undergoes compensatory hypertrophy; associated with absent ipsilateral ureter, seminal vesicle, uterine horn. Often asymptomatic.
- Supernumerary kidney: Extremely rare; accessory separate renal unit; prone to infection.
2. Anomalies of Volume / Hypoplasia
- Renal hypoplasia: Small kidney with reduced nephrons but normal architecture; may cause hypertension in adult life
- Oligomeganephronia: Bilateral hypoplasia with markedly enlarged nephrons; leads to progressive renal failure
3. Anomalies of Position (Renal Ectopia)
- Simple ectopia: Kidney fails to ascend; remains in pelvis (pelvic kidney), iliac fossa, or lumbar region
- Pelvic kidney: Lies in the true pelvis; associated with anomalous vessels, malrotation, PUJ obstruction; may cause dystocia in females
- Crossed ectopia: One or both kidneys cross the midline; usually with fusion
4. Anomalies of Fusion
- Horseshoe kidney: Most common fusion anomaly (1 in 400); lower poles fused across midline by isthmus; isthmus lies in front of aorta, catching on inferior mesenteric artery during normal ascent → kidney remains at L3–L4 level; associated with PUJ obstruction, stones, infection, Wilms' tumour; diagnosis: IVU shows "flower-vase" pattern with medially-directed calyces
- Disc (pancake) kidney: Complete fusion into flat disc in pelvis
5. Anomalies of Rotation
- Malrotation: Renal pelvis faces anteriorly (incomplete rotation) or posteriorly (over-rotation); often coexists with ectopia; can cause PUJ obstruction due to malpositioned ureter
6. Cystic Diseases of the Kidney
- Autosomal Dominant Polycystic Kidney Disease (ADPKD): PKD1 (chromosome 16) and PKD2 (chromosome 4) mutations; bilateral multiple cysts; presents in adulthood with haematuria, hypertension, flank pain, renal failure; associated with intracranial aneurysms (10–15%), cysts in liver/pancreas/spleen
- Autosomal Recessive PKD (ARPKD): Presents in infancy/childhood; bilateral renal enlargement; hepatic fibrosis; poor prognosis
- Multicystic dysplastic kidney (MCDK): Non-functioning kidney replaced by cysts; commonest palpable renal mass in neonates; most involute spontaneously; contralateral kidney must be checked
- Simple renal cysts: Not truly congenital; develop with age; Bosniak classification I–IV guides management
7. Duplex System
- Bifid ureter or complete duplex (two separate ureters, two separate orifices); Weigert-Meyer rule: upper moiety ureter enters bladder inferiorly and medially (ectopic — associated with obstruction/ureterocele); lower moiety ureter inserts superolaterally (associated with reflux)
8. Anomalies of the Ureteropelvic Junction (PUJ Obstruction) — see Part B below
9. Other — Retrocaval Ureter
- Right ureter passes behind the IVC ("reverse J" sign on IVU); causes right-sided hydronephrosis; treated by ureteric division and re-anastomosis anterior to IVC
PART B: PELVI-URETERIC JUNCTION (PUJ) OBSTRUCTION
Definition: Obstruction to urine flow from the renal pelvis into the ureter at the PUJ; the commonest cause of unilateral hydronephrosis. Incidence 1 in 500 live births. (Bailey & Love 28e, Chapter 82)
Aetiopathology
Intrinsic causes (more common):
- Aperistaltic (adynamic) segment at PUJ — muscular hypoplasia / fibrosis with abnormal arrangement of smooth muscle fibres → failure of peristaltic propagation
- High ureteral insertion into the renal pelvis
- Ureteral kinks and valves
- Polyp at PUJ (rare)
Extrinsic causes:
- Crossing aberrant vessel (lower pole artery) — the most common extrinsic cause; a lower polar branch of the renal artery crosses anterior to the PUJ causing compression; important because simple division of the vessel is insufficient — pyeloplasty must be performed
- Fibrous band / adhesions
- Renal calculi secondary to urinary stasis
Secondary PUJO: Following trauma, instrumentation, or retroperitoneal fibrosis.
Associations: More common in males, left side; bilateral in 10%; associated with horseshoe kidney, ectopic kidney, contralateral multicystic kidney.
Pathophysiology
Obstruction → back-pressure → progressive dilatation of renal pelvis and calyces (hydronephrosis) → tubular atrophy → cortical thinning → loss of renal parenchyma → reduced renal function. Stasis predisposes to UTI and stone formation.
Clinical Features
Antenatal: Detected as antenatal hydronephrosis on maternal ultrasonography (commonest cause). Further evaluation required postnatally after 48–72 hours.
Infants / Children: Palpable flank mass (formerly the classic presentation); recurrent UTI; failure to thrive; haematuria; hypertension (rarely).
Adults: Intermittent flank/loin pain; dull ache or episodic severe colicky pain; Dietl's crisis — episodes of severe flank pain after drinking large volumes of fluid, followed by passage of large quantities of urine (partial intermittent obstruction); recurrent pyelonephritis; haematuria.
Examination: Ballotable mass in flank; tenderness in loin.
Investigations
-
Ultrasound (USG): First-line; shows dilated renal pelvis (>10 mm AP diameter is significant) and calyces; assesses parenchymal thickness; echogenicity reflects cortical quality.
-
Isotope Diuresis Renography (MAG3 or DTPA scan): Investigation of choice. Provides:
- Differential renal function (DRF): < 40% in affected kidney = significant functional impairment = surgical indication
- Drainage (washout): T½ >20 minutes after frusemide = obstruction (normal T½ <10 minutes)
- Pattern: Rising (obstructive) curve vs. prompt washout
-
Intravenous Urography (IVU): Shows dilated pelvi-calyceal system; delayed excretion; may show crossing vessels (extrinsic PUJO); increasingly replaced by CT-IVU.
-
CT Urography (CTU): Delineates anatomy; identifies crossing vessels; detects calculi and associated anomalies.
-
MR Urography (MRU): Preferred in children (no radiation); functional information possible.
-
Whitaker test: Antegrade pressure-flow test; invasive; used when isotope renography equivocal; pressure >22 cm H₂O = obstruction.
Indications for Surgical Intervention:
- DRF < 40% and/or worsening
- T½ > 20 minutes on diuresis renogram
- Progressive increase in hydronephrosis on serial USS
- Recurrent UTI, stones, haematuria
- Symptomatic Dietl's crisis
Treatment — Surgical Options
Anderson-Hynes Dismembered Pyeloplasty (Gold Standard): (Bailey & Love 28e)
- Most widely performed procedure; success rate >90%
- Steps: Excision of the stenotic/aperistaltic segment, spatulation of the ureter, creation of wide funnel-shaped dependent anastomosis between the renal pelvis and ureter, with or without reduction pyeloplasty (for large redundant pelvis)
- Advantages: Can be applied to all causes including crossing vessels (transposition of vessel); excises the abnormal segment; allows reduction of large pelvis
- Access: Laparoscopic (now standard), robotic-assisted, or open (flank/midline)
Endopyelotomy (Endoscopic):
- Antegrade (percutaneous) or retrograde (ureteroscopic) incision of the PUJ under direct vision
- Less invasive; suitable for selected patients (short stricture, good function, no crossing vessel)
- Lower success rate (~75%) than open/laparoscopic pyeloplasty; contraindicated if crossing vessel present
Percutaneous Nephrostomy (PCN):
- Initial temporising procedure for infected/obstructed system or compromised renal function
- Allows function recovery before definitive repair
Nephrectomy:
- If DRF < 10–15% and kidney non-salvageable
Laparoscopic Pyeloplasty: Now standard approach in most centres; comparable success to open; faster recovery; requires intracorporeal suturing.
Robotic Pyeloplasty: Facilitated intracorporeal suturing; particularly useful for redo cases and paediatric patients.
Outcomes: Anderson-Hynes pyeloplasty: success (symptomatic relief + improved drainage) in 90–95% cases. Crossing vessel does not adversely affect outcome if properly transposed.
Q.3 — Medico-Legal Documentation, Clinical Features and Management of Penetrating Abdominal Trauma (20 Marks)
PART A: MEDICO-LEGAL DOCUMENTATION
Penetrating abdominal trauma has direct medico-legal implications. Documentation is a legal obligation and must be meticulous. (Schwartz 11e; S. Das Manual of Clinical Surgery)
Medico-Legal Certificate (MLC) Documentation Must Include:
- Patient identification: Full name, age, sex, address, time of registration
- Time and mode of presentation: Who brought the patient; accompanied by police, relatives
- History of injury: As stated by the patient — exact time, place, mechanism (stabbing, gunshot, sharp object), nature of weapon if known
- Police intimation: All penetrating trauma cases are MLC; police must be intimated immediately, regardless of patient's consent
- Wound description (precise and objective):
- Location (exact anatomical site with measurements)
- Type: Incised wound (sharp edge — clean, linear), lacerated wound, stab wound, firearm entry/exit
- Size: Length × width × depth in centimetres
- Shape: Oval, spindle, circular
- Margins: Sharp, ragged, inverted/everted
- Edges: Regular or irregular
- Wound track: Direction, estimated depth
- Entry vs. exit wound for gunshots: Entry — small, punched-out, inverted, abrasion collar; Exit — large, irregular, everted
- Number of wounds: Each documented separately
- Whether wound probes/instruments have been introduced
- Vital signs at presentation: BP, HR, GCS, O₂ saturation, temperature
- Associated injuries: Thoracic involvement, visceral evisceration
- Time of examination, signature, registration number of examining doctor
- Clothing: Preservation of clothing for forensic analysis; note tears, bloodstains, gunpowder marks
- Chain of evidence: All evidence (bullets, weapons fragments) handed to police with acknowledgement
- Consent: Informed surgical consent even in emergencies, or consent from relatives/two doctors when unconscious
- Operative findings: All must be documented in OT notes; organs injured, degree, repair performed
- Prognosis: Simple hurt / grievous hurt / dangerous to life — guided by findings
PART B: CLINICAL FEATURES
Mechanism of Injury
Stab wounds: Caused by knives, glass, metal objects; energy transfer limited to direct wound track. Most commonly injured: small bowel (50%) > liver (40%) > colon (20%). Low-velocity, predictable.
Gunshot wounds (GSW):
- Low-velocity (<600 m/s): wound track along bullet path
- High-velocity (>600 m/s): cavitation effect → extensive blast injury far beyond bullet track; unpredictable trajectory
- Most commonly injured: small bowel > colon > liver > abdominal vessels
Evisceration: Protrusion of viscera (usually omentum or small bowel) through wound — indicates peritoneal penetration.
Assessment — Primary Survey (ATLS Protocol)
- Airway — open, protect cervical spine if indicated
- Breathing — assess for haemothorax, pneumothorax (GSW thoracoabdominal)
- Circulation — assess for haemorrhagic shock (Class I–IV), IV access, resuscitation
- Disability — GCS, pupillary response
- Exposure — complete exposure; log roll; examine back, flanks, perineum, groin
Clinical Features of Penetrating Abdominal Injury:
Signs of peritoneal penetration:
- Evisceration (absolute indication for laparotomy)
- Peritonitis: generalised guarding, rigidity, rebound tenderness
- Free gas on erect CXR or CT
- Haemodynamic instability
Signs of hollow viscus injury:
- Diffuse peritonitis, board-like rigidity
- Free gas under diaphragm
- Bilious peritoneal fluid
Signs of solid organ / vascular injury:
- Haemoperitoneum: progressive abdominal distension, shoulder-tip pain
- Haemodynamic instability
- FAST positive (free fluid)
Specific features by wound site:
- Epigastric stab: Stomach, liver, spleen, transverse colon at risk
- Right hypochondriac: Liver, right colon
- Left hypochondriac: Spleen, stomach, left colon, tail of pancreas
- Flank wounds: Retroperitoneal organs — colon, kidney, duodenum, vessels
- Pelvic wounds: Bladder, rectum, iliac vessels
- Thoracoabdominal (between nipple line and costal margin): May injure diaphragm + abdominal viscera; high index of suspicion for diaphragmatic injury
PART C: INVESTIGATIONS
-
FAST (Focused Abdominal Sonography for Trauma): Bedside; detects free fluid in Morrison's pouch, perihepatic, perisplenic, pelvic spaces, and pericardium. Positive FAST + haemodynamic instability = emergency laparotomy.
-
CT scan abdomen/pelvis with IV contrast: Gold standard for haemodynamically stable patients; delineates organ injury, active bleeding, free air, retroperitoneal injuries; guides non-operative management.
-
Plain X-rays: Erect CXR — pneumoperitoneum; AXR — bullet trajectory, retained foreign body; Chest AP.
-
Diagnostic Peritoneal Lavage (DPL): Largely replaced by CT/FAST; positive if >10 ml blood aspirated, RBC >100,000/mm³, WBC >500/mm³, bile/faeces/food fibres.
-
Diagnostic Laparoscopy: Highly accurate for peritoneal penetration; preferred for haemodynamically stable patients with uncertain peritoneal breach; allows therapeutic laparoscopy in skilled hands.
-
Bloods: FBC, coagulation screen, G&S/crossmatch, U&E, LFTs, amylase, ABG, lactate (assess shock severity).
PART D: MANAGEMENT
Haemodynamically Unstable — Emergency Laparotomy (First Priority)
Absolute indications for emergency laparotomy:
- Haemodynamic instability not responding to resuscitation
- Evisceration
- Clinical peritonitis
- Positive FAST in unstable patient
- GSW to abdomen (most require laparotomy)
- Impalement injuries
Haemodynamically Stable — Selective Non-Operative Management (NOM)
NOM applies mainly to stab wounds in stable patients:
- Serial clinical examinations (minimum 24 hours)
- CT-guided NOM for isolated solid organ injuries without vascular injury on CT
- DL or CT to assess peritoneal penetration
- Patients requiring NOM need: ICU monitoring, accessible emergency theatre, surgeon available 24/7
Operative Principles — Damage Control Surgery (DCS)
Employed in unstable patients (the "lethal triad": hypothermia, acidosis, coagulopathy):
- Stage 1 — Abbreviated laparotomy: Haemostasis (packing), contamination control (stapled bowel division), temporary closure (Bogota bag)
- Stage 2 — ICU resuscitation: Correct physiology — warm, correct coagulopathy, optimise
- Stage 3 — Definitive repair: Return to theatre within 24–72 hours for formal repair and bowel continuity
Specific Organ Management:
- Liver: Packing for haemostasis (Pringle manoeuvre if needed); tractotomy for through-and-through injuries; hepatic arterial embolisation for persistent bleeding (angio-suite)
- Spleen: Splenorrhaphy for minor lacerations; splenectomy for major injuries; post-splenectomy vaccinations (pneumococcus, meningococcus, H. influenzae)
- Small bowel: Primary repair for simple lacerations (<50% circumference); segmental resection and anastomosis; defer anastomosis in DCS
- Colon: Historically mandatory colostomy; now primary repair acceptable for right colon in stable patients; left colon injuries — colostomy in unstable/contaminated
- Duodenum: Primary repair; pyloric exclusion + gastrojejunostomy for severe injuries; rare pancreatic injury needs drainage ± Whipple's
- Bladder: Two-layer repair; urinary catheter drainage 7–10 days
- Vascular injuries: Aorta/IVC — primary repair or interposition graft; damage control with shunting if unstable
- Diaphragm: Primary repair with non-absorbable suture; left-sided injuries require thorough inspection to rule out gastric/splenic injury
Q.4 — Evaluate Clinical Scenarios: Aetiopathology and Management (20 Marks)
SCENARIO (a): Post-LSCS Puerperial Patient with Painful Oedema of Lower Limb
Diagnosis: Deep Vein Thrombosis (DVT)
Aetiopathology — Virchow's Triad (Bailey & Love 28e)
The triad of venous stasis, endothelial damage, and hypercoagulability are all operative after LSCS:
-
Venous stasis:
- Immobility post-LSCS (pain, regional anaesthesia)
- Pelvic veins compressed by gravid uterus → venous stasis in lower limbs
- Prolonged operative time
-
Endothelial damage:
- Surgical trauma to pelvic veins during LSCS
- Instrumental delivery or uterine manipulation
- Catheterisation
-
Hypercoagulability:
- Pregnancy is a prothrombotic state: increased factors II, VII, VIII, X, XII, vWF, fibrinogen
- Decreased Protein S (natural anticoagulant)
- Increased PAI-1 and PAI-2 (decreased fibrinolysis)
- This hypercoagulable state persists for 6–8 weeks post-partum
- LSCS carries 2–3× higher DVT risk compared to vaginal delivery
Additional risk factors in this patient: Post-operative state, puerperal period, probable reduced mobility, possible sepsis (infection at operative site).
Pathology: Thrombus forms most commonly in calf veins (sural veins) and propagates proximally to popliteal and femoral veins. Propagation to the ileofemoral segment is dangerous — risk of pulmonary embolism increases dramatically with proximal DVT.
Clinical Features
Symptoms:
- Painful swelling of the lower limb (classically left side — iliac vein compressed by right common iliac artery)
- Calf pain; pain on walking
- Low-grade fever (thrombophlebitis)
- Skin feels tense and shiny
Signs:
- Pitting oedema of affected limb
- Tenderness in calf, popliteal fossa, or along femoral vein
- Homan's sign: Calf pain on passive dorsiflexion of foot (unreliable — positive in only 30%; may dislodge thrombus)
- Moses' sign: Pain on compression of calf from medial to lateral
- Increased skin temperature over affected limb
- Dilated superficial veins
- In phlegmasia alba dolens (white leg): severe ileofemoral DVT → arterial spasm → pale, cold, swollen limb
- In phlegmasia cerulea dolens (blue leg): massive iliofemoral DVT → venous gangrene risk
Wells Score for Clinical Probability:
Used to guide investigation — score ≥2 = high probability; <2 = low probability.
Investigations
- Compression Duplex Ultrasound (Gold standard for clinical DVT): Non-compressibility of vein is diagnostic; visualises thrombus; assesses flow; sensitivity 95% for proximal DVT.
- D-dimer: Negative D-dimer + low clinical probability = rules out DVT (high NPV). Not useful for ruling in (low specificity — elevated in pregnancy, post-surgery always).
- Venography: Gold standard but invasive; rarely needed; used when US inconclusive.
- CT pulmonary angiography (CTPA): If pulmonary embolism suspected.
- Thrombophilia screen: Lupus anticoagulant, anticardiolipin antibodies, Factor V Leiden, Protein C/S, Antithrombin III — tested after anticoagulation complete.
Management
Initial:
- Elevation of limb
- Graduated elastic compression stockings (GCS — Class II)
- Analgesia (NSAIDs, paracetamol)
Anticoagulation:
- Low molecular weight heparin (LMWH): Drug of choice during puerperium; safe during breastfeeding; Enoxaparin 1 mg/kg BD or 1.5 mg/kg OD; start immediately on diagnosis
- Continue LMWH minimum 6 weeks post-partum total (or transition to warfarin after 5 days if not breastfeeding)
- Warfarin: Safe in breastfeeding; INR target 2–3; can be started after LMWH bridge
- DOACs (Rivaroxaban, Apixaban): Avoid in breastfeeding (limited data)
- Duration: 3–6 months total; 6–12 months if thrombophilia/recurrent DVT
Catheter-directed thrombolysis: For massive ileofemoral DVT with threatened viability (phlegmasia cerulea dolens); not standard first-line.
IVC filter: If anticoagulation absolutely contraindicated (e.g., recent haemorrhage) and high PE risk.
Thromboprophylaxis post-LSCS (Prevention):
- All women undergoing LSCS should receive LMWH prophylaxis for minimum 7 days post-partum; high-risk women (BMI >40, previous DVT, thrombophilia) for 6 weeks.
- Early mobilisation, hydration, TED stockings intraoperatively.
SCENARIO (b): Chronic Alcoholic with Chronic Upper Abdominal Pain Radiating to Back + Oil-Containing Foul-Smelling Stools
Diagnosis: Chronic Pancreatitis with Exocrine Insufficiency (Steatorrhoea)
Aetiopathology (Schwartz 11e; Sabiston; Bailey & Love 28e)
Causes (TIGAR-O classification):
- Toxic-metabolic: Alcohol (most common — 70–80% of cases in adults), smoking, hypercalcaemia, hypertriglyceridaemia, CKD
- Idiopathic: Tropical pancreatitis (cassava toxin + malnutrition — endemic in India/Africa)
- Genetic: PRSS1, SPINK1, CFTR mutations — hereditary pancreatitis
- Autoimmune: IgG4-related, type 1 and type 2
- Recurrent acute pancreatitis
- Obstructive: IPMN, SOD, divisum
Alcohol mechanism: Alcohol → toxic metabolites (acetaldehyde) → damage acinar cells → premature activation of trypsinogen → inflammatory cascade → repeated injury → fibrosis → ductal strictures → upstream dilatation → stones → further obstruction. Loss of both exocrine and endocrine function follows.
Steatorrhoea mechanism: Exocrine insufficiency occurs when >90% of pancreatic exocrine function is lost. Pancreatic lipase and co-lipase deficiency → fat malabsorption → steatorrhoea (bulky, pale, greasy, foul-smelling, oil-floating stools). This is a late manifestation of chronic pancreatitis.
Clinical Features
Symptoms:
- Chronic, recurrent upper abdominal/epigastric pain — characteristically radiates to the back (retroperitoneal inflammation); partially relieved by leaning forward ("prayer position"), worse after fatty meals
- Pain may be constant or episodic
- Anorexia, nausea, vomiting
- Significant weight loss (malnutrition + fear of eating)
- Steatorrhoea: Bulky, pale, greasy, oily, foul-smelling stools; floats in water; difficult to flush; oil droplets visible
- Late: Diabetes mellitus (endocrine insufficiency — destruction of islets of Langerhans)
- Jaundice (bile duct stricture from periductal fibrosis or pancreatic head mass)
Signs:
- Epigastric tenderness; mass (pseudocyst in 30%)
- Signs of malnutrition: wasting, peripheral oedema, glossitis
- Signs of chronic liver disease from alcohol (cirrhosis concurrent)
- Ecchymosis: Grey Turner's (flanks), Cullen's (periumbilical) — in acute exacerbations
Investigations
Functional:
- Faecal elastase-1: <200 μg/g = exocrine insufficiency (sensitive, non-invasive, widely used)
- Serum lipase/amylase: Normal or low in burnt-out chronic disease; elevated in acute exacerbations
- 72-hour faecal fat: >7 g/day = steatorrhoea (gold standard but cumbersome)
- Blood glucose / HbA1c: Assess endocrine function (pancreatogenic diabetes Type 3c)
Imaging:
- CECT abdomen: Shows pancreatic calcifications (pathognomonic of chronic pancreatitis), ductal dilatation, atrophy, pseudocysts; rules out carcinoma
- MRCP: Non-invasive; best ductal imaging; shows "chain of lakes" pattern (alternating strictures and dilatation of MPD); identifies stones
- EUS: Sensitive for early disease; ductal and parenchymal features (Rosemont criteria); allows FNA to exclude malignancy
- ERCP: Reserved for therapeutic intervention (stenting, stone removal)
- Plain AXR: Pancreatic calcifications visible in advanced disease
Management
Conservative (Medical):
- Alcohol cessation and smoking cessation — most important; arrests disease progression
- Analgesia: WHO ladder; paracetamol → NSAIDs → tramadol → opioids (morphine); celiac plexus block for refractory pain
- Pancreatic enzyme replacement therapy (PERT): Creon (pancrelipase) with every meal and snack; 50,000–80,000 IU lipase per main meal; taken during meals; reduces steatorrhoea and malnutrition
- Fat-soluble vitamin supplementation: Vitamins A, D, E, K
- Diet: Low-fat, high-protein, small frequent meals; medium-chain triglycerides
- Diabetes management: Insulin therapy (pancreatogenic DM is brittle — glucagon deficiency also present → hypoglycaemia risk)
- Antioxidants: Selenium, Vitamins C and E — evidence limited
Endoscopic:
- ERCP with sphincterotomy, stone extraction, pancreatic duct stenting for dominant strictures
- EUS-guided celiac plexus block: refractory pain
- EUS/endoscopic pseudocyst drainage
Surgical — indications: Refractory pain, ductal obstruction, inability to exclude malignancy, pseudocyst complications, bile duct/duodenal obstruction.
Surgical procedures:
- Dilated duct (MPD >6–7 mm): Lateral pancreaticojejunostomy (Puestow-Gillesby / Frey procedure) — side-to-side anastomosis of longitudinally opened MPD with Roux loop of jejunum; drainage procedure; 80% pain relief
- Pancreatic head mass ("inflammatory"): Beger procedure (duodenum-preserving pancreatic head resection) or Frey procedure (local head resection + lateral PJ)
- Whipple's pancreaticoduodenectomy (PD): For head-dominant disease especially when malignancy cannot be excluded
- Distal pancreatectomy: For body/tail dominant disease
- Total pancreatectomy: End-stage disease with severe pain and diabetes already present
Q.5 — Write Notes On: (a) Recent Advances in Management of Ventral Hernia; (b) LASER in Uro-Ano-Rectal Diseases (20 Marks — 10 each)
PART A: RECENT ADVANCES IN MANAGEMENT OF VENTRAL HERNIA (10 Marks)
Definition: Ventral hernias include incisional hernias, epigastric hernias, umbilical hernias, and paraumbilical hernias — herniation of abdominal contents through defects in the anterior abdominal wall.
Incisional hernia is the most clinically significant: occurs in 10–15% of laparotomy wounds; risk factors: infection, obesity, malnutrition, steroids, poor technique, raised intra-abdominal pressure.
1. Mesh Technology Advances
Traditional: Heavyweight polypropylene mesh — effective but caused chronic pain, reduced abdominal wall compliance, adhesions.
Modern mesh types:
- Lightweight macroporous polypropylene: Reduced foreign body reaction; better compliance
- Biological meshes (Permacol, Strattice, AlloDerm): Acellular dermal matrix from human or porcine dermis; ideal for contaminated/infected fields (grade 3–4 wounds); more expensive; may be permanent or temporary bridge
- Biosynthetic absorbable meshes (TIGR, BIO-A): Slowly absorbed over 12–18 months; scaffolds native tissue ingrowth; used in contaminated fields with lower infection risk
- Self-gripping meshes (Progrip): Microhooks avoid need for tacking; less seroma
- Anti-adhesion coated meshes (Proceed, Sepramesh, Parietex Composite): Visceral surface coated with absorbable film (oxidised cellulose / hyaluronic acid) → reduces bowel adhesion → safe for intraperitoneal placement (IPOM technique)
2. Techniques — Laparoscopic Repair
Laparoscopic IPOM (IntraPeritoneal Onlay Mesh):
- Classic technique: composite mesh placed intraperitoneally, overlapping defect by ≥5 cm; fixed with tackers/sutures
- Advantages: No wound opening, reduced SSI, shorter hospital stay
Laparoscopic IPOM Plus:
- Defect is sutured laparoscopically before mesh placement; reduces recurrence and seroma
3. Robotic-Assisted Repair
- Robot allows precise intracorporeal suturing for defect closure and mesh fixation
- Robotic Transabdominal Preperitoneal (rTAPP) hernia repair: Mesh placed in extraperitoneal plane; avoids intraperitoneal mesh entirely — eliminates visceral adhesion risk
- Robotic Extended Totally Extraperitoneal (eTEP): For large defects; mesh in retromuscular/Retzius space
4. Component Separation Techniques (CST)
For large complex hernias with loss of domain:
Open Anterior CST (Ramirez technique): Release of external oblique aponeurosis allows medial advancement of rectus complex by 5 cm at waist; enables fascial closure of large defects.
Minimally Invasive Posterior CST — Transversus Abdominis Release (TAR): Posterior approach; division of transversus abdominis posterior to rectus allowing wide retromuscular space creation and mesh placement; up to 10 cm advancement per side; avoids skin flap elevation → reduced skin necrosis and SSI.
5. EHS / VHWG Classification Guides Surgery
- European Hernia Society (EHS) classification grades defects M1–M5 by location and W1–W3 by width
- Ventral Hernia Working Group (VHWG) Grades 1–4 guide mesh choice in contaminated fields
6. Management of Complex / Contaminated Hernias
- Pre-operative optimisation: Smoking cessation, weight loss (BMI <35), blood sugar control, nutritional optimisation
- Botulinum toxin injection (BTA) into lateral abdominal wall muscles 4–6 weeks pre-op: chemically paralyses muscles → elongation → facilitates midline fascial closure → reduces loss of domain
- Serial Preoperative Progressive Pneumoperitoneum (SPPP): For giant hernias with loss of domain
7. ERAS in Hernia Surgery
- Multimodal analgesia, early feeding and mobilisation, reduced opioids, goal-directed fluid therapy → faster recovery
8. Recurrence Reduction
- Defect closure + mesh (IPOM Plus / retromuscular) reduces recurrence from ~30% (simple repair) to <5% (mesh)
- Adequate mesh overlap (≥5 cm), proper fixation, defect closure are key
- Long-term outcome data favours retromuscular (sublay) mesh placement (Rives-Stoppa repair) as gold standard for elective incisional hernia
PART B: LASER in Uro-Ano-Rectal Diseases (10 Marks)
LASER = Light Amplification by Stimulated Emission of Radiation
Laser energy uses focused, monochromatic, coherent light to cut, coagulate, vaporise, or ablate tissue with minimal thermal spread, precision, and haemostasis.
Types of Lasers Used in Surgery:
| Laser Type | Wavelength | Tissue effect | Main use |
|---|---|---|---|
| CO₂ laser | 10,600 nm | Absorbed by water; vaporisation/cutting | Anal condylomata, peri-anal lesions |
| Nd:YAG laser | 1064 nm | Deep tissue penetration; coagulation | Endoscopic haemostasis, BPH |
| KTP (Greenlight) | 532 nm | Absorbed by haemoglobin; vaporisation | BPH (PVP) |
| Holmium:YAG (Ho:YAG) | 2100 nm | Absorbed by water; precise cutting + lithotripsy | HoLEP, ureteric stones, UTUC |
| Thulium | 1940 nm | Water absorption; efficient vapoenucleation | ThuVEP, ThuFLEP for BPH |
| LASER for piles | 980 nm diode | Submucosal ablation | HeLP, LHP procedures |
LASER IN UROLOGICAL DISEASES
1. Benign Prostatic Hyperplasia (BPH):
-
Holmium Laser Enucleation of Prostate (HoLEP): Gold standard laser technique for BPH of any size; enucleates entire transition zone in anatomical planes using Ho:YAG laser (2100 nm); equivalent to TURP/open prostatectomy with less bleeding, shorter catheterisation, shorter hospital stay; tissue available for histology (important to exclude cancer); suitable for glands >80 g; no size limit; learning curve is steep.
-
Greenlight Laser (KTP/532 nm — PVP: Photoselective Vaporisation of Prostate): Absorbed selectively by haemoglobin-rich prostatic tissue → vaporisation; excellent haemostasis; suitable for anticoagulated patients; no tissue for histology; suitable for small-moderate glands.
-
Thulium Laser VapoEnucleation (ThuVEP) / ThuFLEP: Similar to HoLEP with potentially smoother cutting; continuous wave emission.
2. Ureteric and Renal Calculi:
-
Holmium laser (Ho:YAG) lithotripsy: Single most effective intracorporeal lithotripsy for all stone types; used via ureteroscope (flexible or semi-rigid); fragmentises or dusts stones to <1 mm (Pulse Modulation / "Dusting" technique); dusting technique avoids basket retrieval; outpatient procedure.
-
Thulium Fibre Laser (TFL): Newer; 5× more efficient than Ho:YAG for stone dusting; greater pulse energy control; smaller fibres allow use in smaller scopes.
3. Upper Tract Urothelial Carcinoma (UTUC):
- Ho:YAG laser ablation via ureteroscope for low-grade, small (<1 cm) upper tract TCC in selected patients (solitary kidney, bilateral disease, unfit for nephroureterectomy); tissue ablation with minimal damage to ureteric wall.
4. Bladder Tumours:
- Laser ablation/vaporisation of bladder TCC: Ho:YAG or Nd:YAG for selected small, low-grade papillary tumours; no obturator nerve reflex (advantage over TURBT); no specimen for histology is a disadvantage.
LASER IN ANO-RECTAL DISEASES
1. Haemorrhoids (Piles):
-
HeLP (Haemorrhoidal Laser Procedure) / Laser Haemorrhoidal Dearterialization: 980 nm diode laser applied at the Doppler-identified feeding arteries to coagulate and obliterate them; minimally invasive, no excision, minimal pain, rapid return to work; day-care procedure; suitable for grades II–III; less effective for grade IV.
-
LHP (Laser Haemorrhoidoplasty): Laser fibre inserted into haemorrhoidal cushion submucosal space → photothermal coagulation → shrinkage of cushion + coagulation of feeding vessels; no excision; minimal pain; outpatient procedure; grades II–III.
2. Fistula-in-Ano:
- FiLaC (Fistula-in-Ano Laser Closure): Thin radially emitting laser probe (diode 1470 nm or 980 nm) introduced through fistula tract; laser energy coagulates/destroys fistula tract epithelium and granulation tissue from inside → closure; no sphincter division → sphincter-preserving; suitable for complex fistulae (intersphincteric, transsphincteric) where sphincter preservation is critical; healing rates 60–80%; allows re-treatment if recurrence.
3. Pilonidal Sinus:
- SiLaC (Sinus Laser Closure): Laser probe introduced into sinus tract under endoscopic visualisation → thermal destruction of sinus epithelium → collapse and fibrosis; minimally invasive; heals by secondary intention; faster healing than traditional excision; lower recurrence than simple incision; recurrence 15–20%.
4. Anal Condylomata / Warts:
- CO₂ laser ablation of anal and perianal condylomata acuminata (HPV-related warts); vaporises lesions precisely with minimal thermal spread; can treat large areas in one session; recurrence possible (as HPV remains in latent form).
5. Anal Fissure:
- Diode laser sphincterotomy: Laser energy used to perform lateral internal sphincterotomy via a closed percutaneous approach; minimal incontinence risk (theoretical); limited data compared to conventional open/closed LIS.
6. Rectal Tumours:
- Nd:YAG laser palliative recanalisation of obstructing rectal carcinoma in inoperable patients
- Transanal laser excision for early T1 rectal carcinoma in very selected patients at centres with specific expertise.
Advantages of Laser in Anorectal Surgery: Day-care procedures, minimal pain, rapid recovery, low complication rates, sphincter-preserving, suitable for outpatient/office setting.
Disadvantages: Equipment cost, learning curve, limited long-term data, tissue not always available for histology.
Summary: Mark Allocation Guide
| Question | Topic | Marks |
|---|---|---|
| Q1 | Lymphovascular anatomy (6) + Aetiopathology (4) + Staging (4) + Management (6) | 20 |
| Q2 | Congenital anomalies (8) + PUJO aetiopathology (3) + Clinical features (3) + Investigations (3) + Treatment (3) | 20 |
| Q3 | Medico-legal documentation (6) + Clinical features (6) + Management (8) | 20 |
| Q4a | DVT aetiopathology (4) + Clinical features (3) + Investigations (3) + Management (5) — 10 marks per scenario | 10+10 |
| Q5a | Recent advances ventral hernia | 10 |
| Q5b | LASER in uro-ano-rectal diseases | 10 |
Sources: Bailey & Love's Short Practice of Surgery 28e; Schwartz's Principles of Surgery 11e; S. Das Manual of Clinical Surgery 13e; Sabiston Textbook of Surgery 21e; Current Surgical Therapy 14e; Mulholland & Greenfield's Surgery 7eAll five questions answered in full. Here is a brief guide to what each answer covers:
Quick Navigation
| Q | Diagnosis/Topic | Key Points Covered |
|---|---|---|
| Q1 (20M) | Carcinoma Stomach | Arterial supply (named vessels), lymph node stations N1–N16, D1/D2 dissection, transcoelomic spread; Aetiology (H. pylori/Correa cascade, dietary, genetic), Borrmann + Laurén classification, EGC vs. advanced, TNM staging 8th ed.; Surgery (subtotal/total gastrectomy, D2), FLOT chemotherapy, Trastuzumab, Palliative options |
| Q2 (20M) | Congenital Kidney Anomalies + PUJO | Complete CAKUT classification (agenesis, ectopia, horseshoe, ADPKD, MCDK, duplex, retrocaval ureter); PUJO intrinsic/extrinsic causes, Dietl's crisis, DTPA renogram (DRF <40%, T½ >20 min), Anderson-Hynes pyeloplasty, HoLEP endopyelotomy, laparoscopic/robotic repair |
| Q3 (20M) | Penetrating Abdominal Trauma | MLC documentation checklist (entry/exit wound description, police intimation, chain of evidence); ATLS primary survey; Stab vs. GSW; FAST, CT, DPL, DL; Damage control surgery (lethal triad); Organ-specific management |
| Q4a (10M) | Post-LSCS DVT | Virchow's triad in pregnancy, hypercoagulable state, clinical features (Homan's, Moses', phlegmasia); Wells score; Duplex USS; LMWH (Enoxaparin), duration, prevention |
| Q4b (10M) | Chronic Pancreatitis + Steatorrhoea | TIGAR-O aetiology, alcohol mechanism, exocrine insufficiency (90% loss), faecal elastase, MRCP "chain of lakes"; PERT (Creon), alcohol cessation, Lateral PJ (Puestow/Frey), Beger procedure, Whipple's |
| Q5a (10M) | Recent Advances Ventral Hernia | Biological/biosynthetic/anti-adhesion meshes, laparoscopic IPOM Plus, robotic rTAPP/eTEP, TAR (posterior CST), botulinum toxin, ERAS, Rives-Stoppa |
| Q5b (10M) | LASER in Uro-Ano-Rectal | HoLEP, Greenlight (PVP), ThuVEP for BPH; Ho:YAG lithotripsy, TFL for stones; HeLP/LHP for haemorrhoids; FiLaC for fistula-in-ano; SiLaC for pilonidal sinus; CO₂ for anal warts |
Smoking index
Smoking Index (SI) = Number of cigarettes smoked per day × Number of years of smoking
A Smoking Index ≥ 300 is considered significant for risk of chronic obstructive pulmonary disease (COPD) and other smoking-related diseases. An SI ≥ 400 is a significant risk factor for lung cancer.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Smoking Index
Definition and Formula
Smoking Index (SI) = Number of cigarettes smoked per day × Number of years of smoking
This is the standard formula used in Indian clinical practice and surgical/pulmonology examinations.
Example: A patient who smokes 20 cigarettes/day for 15 years has an SI = 20 × 15 = 300
Clinical Significance / Cut-offs
| Smoking Index | Interpretation |
|---|---|
| < 100 | Low risk |
| 100 – 299 | Moderate risk — monitor |
| ≥ 300 | Significant risk — COPD, chronic bronchitis, peripheral vascular disease |
| ≥ 400 | High risk for lung carcinoma |
Pack-Year Index (International Equivalent)
The term used in Western/international textbooks is the Pack-Year:
Pack-Years = (Cigarettes smoked per day ÷ 20) × Number of years smoked
Since 1 pack = 20 cigarettes, a person smoking 20 cigs/day for 10 years = 10 pack-years.
| Pack-Years | Clinical Relevance |
|---|---|
| ≥ 10 pack-years | Threshold for HPV+ head & neck cancer risk stratification |
| ≥ 20 pack-years | Lung cancer screening eligibility (USPSTF / NLST criteria) |
| > 30 pack-years | Strong COPD risk (Robbins Pathology) |
| > 40 pack-years | Very high COPD / lung malignancy risk |
Conversion: SI of 300 ≈ 15 pack-years; SI of 400 ≈ 20 pack-years.
Uses of Smoking Index in Clinical Practice
- COPD risk assessment — SI ≥300 = clinically significant smoking history; correlates with spirometric obstruction
- Lung cancer screening — USPSTF recommends annual low-dose CT (LDCT) for patients aged 50–80 with ≥20 pack-years who currently smoke or quit within 15 years
- Surgical risk stratification — pre-operative pulmonary risk; smoking cessation advised ≥8 weeks before elective surgery
- Head & neck oncology — ≤10 vs. >10 pack-years distinguishes low/high-risk groups in HPV+ oropharyngeal carcinoma (Schwartz 11e)
- Buerger's disease — heavy smoking (high SI) in young males is the single most important diagnostic criterion
- Cardiovascular risk — every 10 pack-year increment increases MI/stroke risk
- Lung donor assessment — smoking history <20 pack-years is a standard donor criterion (Bailey & Love 28e)
Heaviness of Smoking Index (HSI)
A separate validated questionnaire tool measuring nicotine dependence (not the same as SI):
- Based on 2 parameters: cigarettes per day and time to first cigarette after waking
- Score 0–6; higher score = greater nicotine dependence
- Used to guide cessation therapy (NRT dosing, varenicline)
(Fuster & Hurst's The Heart, 15e)
Bottom line for exams: Smoking Index = cigs/day × years smoked. SI ≥300 = significant risk for COPD/PVD; SI ≥400 = significant risk for lung cancer. International equivalent is Pack-Years (divide SI by 20).
Hyperasthesia in peripheral arterial disease
In peripheral arterial disease, hyperaesthesia refers to increased skin sensitivity at the border zone between viable and gangrenous/ischaemic tissue. It is a specific clinical sign described in S. Das and is the opposite of the anaesthesia seen in the ischaemic core.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Got the exact textbook quote. Let me also get the broader neurological examination section for context.
Reading File
Finding Sources
Hyperaesthesia in Peripheral Arterial Disease
The Textbook Statement (S. Das, Manual of Clinical Surgery, 13e)
"Sensation of the gangrenous area is often lost. The patient is unable to move the part when the viability of the deeper tissues becomes at stake. On the border line of the gangrene the skin becomes hyperaesthetic." — S. Das, Chapter 6: Peripheral Vascular Disease, p. 92
What is Hyperaesthesia Here?
Hyperaesthesia = abnormally increased sensitivity of the skin to stimuli (touch, pinprick, temperature) — the opposite of anaesthesia/hypoaesthesia.
In the context of peripheral arterial disease and gangrene, it is a neurological sign found specifically at the demarcation zone between ischaemic/dead tissue and viable tissue.
Pathophysiology — Why Does Hyperaesthesia Occur at the Border?
Understanding this requires knowing how ischaemia affects peripheral nerves in a spatial and temporal gradient:
Zone 1 — Gangrenous Core (Central ischaemic area)
- Complete ischaemia → anaesthesia (total loss of sensation)
- Peripheral nerves are exquisitely sensitive to ischaemia — among the first tissues to lose function
- C-fibres (pain) and A-delta fibres (temperature/sharp pain) die earliest
- Motor function also lost — patient cannot move the gangrenous part
- Skin: black, mummified (dry gangrene) or necrotic (wet)
Zone 2 — Border Zone / Demarcation Line (Transitional area)
- Partial ischaemia — blood supply is just enough to keep nerves alive but not enough for normal function
- Relative ischaemia + inflammatory mediators released from necrotic tissue (prostaglandins, bradykinin, histamine, substance P, TNF-α) sensitise peripheral nociceptors
- C-fibres become sensitised (peripheral sensitisation) → lowered threshold to stimulation → hyperaesthesia
- This is analogous to the tender, hyperaesthetic skin around any area of local inflammation/tissue injury
- The demarcation line is also the zone of reactive inflammation — vasodilatation, oedema, immune cell infiltration
Zone 3 — Viable Proximal Tissue
- Normal or near-normal sensation
- May show trophic changes (hair loss, shiny skin) if chronic ischaemia is present
Clinical Significance
| Feature | Significance |
|---|---|
| Hyperaesthesia at border | Marks the demarcation line — helps define extent of gangrene |
| Anaesthesia of core | Confirms non-viability of gangrenous tissue |
| Useful for amputation planning | Amputate at or proximal to the zone of normal sensation to ensure tissue viability |
| Distinguishes dry from early wet gangrene | Wet gangrene may show broader zone of hyperaesthesia due to spreading infection and inflammation |
| Prognostic value in acute limb ischaemia | Presence of paraesthesia/anaesthesia = severe ischaemia (Rutherford IIb/III); neurological deficit → irreversible ischaemia impending |
Spectrum of Sensory Changes in PAD (Summary)
Proximal viable tissue Border zone Gangrenous core
↓ ↓ ↓
Normal sensation HYPERAESTHESIA ANAESTHESIA
(sensitised nociceptors, (nerves dead /
inflammatory mediators) non-functional)
Related Neurological Examination Points in PAD (S. Das 13e)
- Sensation: Test with pin-prick and light touch across the ischaemic limb — maps zones of sensory loss
- Motor function: Patient is unable to move the gangrenous part when deeper tissues are non-viable — motor nerves equally ischaemia-sensitive
- Neurological deficit in Acute Limb Ischaemia (ALI): Paraesthesia → anaesthesia → paralysis = sequential, worsening ischaemia; paralysis = surgical emergency (irreversible within 4–6 hours)
- Central nervous system causes of sensory loss must be excluded in superficial ulceration: hemiplegia, transverse myelitis, syringomyelia, tabes dorsalis (S. Das 13e)
Exam-Ready Summary
Hyperaesthesia in PAD is the increased skin sensitivity found at the border line of gangrene in peripheral arterial disease. It is caused by sensitisation of peripheral nociceptors by ischaemia-induced inflammatory mediators at the demarcation zone. Central to this zone is anaesthesia (dead nerves), and proximal to it is normal sensation. Clinically, it helps define the extent of gangrene, guides the level of amputation, and indicates that the tissue at the border is still viable but severely stressed. (S. Das, Manual of Clinical Surgery 13e, p. 92)
Intraductal pailloma treatment
Intraductal papilloma of the breast is treated by microdochectomy (excision of the affected duct segment). The key principle is complete excision to both treat and exclude malignancy.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Excellent - very detailed content from Bailey & Love, Fischer's Mastery of Surgery, and Pye's. Now I have everything needed for a comprehensive answer.
Intraductal Papilloma — Treatment
What Is It?
Intraductal papilloma is a benign epithelial tumour arising from the ductal epithelium of the breast. It is the most common cause of bloody/blood-stained nipple discharge in women aged 35–55. The tumour grows on a fibrovascular stalk within a major lactiferous duct, typically within 5 cm of the nipple (subareolar/central).
Pre-Treatment Assessment — Triple Assessment (Mandatory)
Before any treatment, triple assessment is essential to exclude carcinoma:
| Component | Finding in Papilloma |
|---|---|
| Clinical examination | Soft periareolar mass ± expressible bloody discharge from a single duct; trigger point identifies the duct |
| Imaging (USS ± mammogram) | USS: dilated subareolar duct + intraluminal filling defect (diagnostic accuracy 85%); Mammogram: retroareolar opacity or microcalcification |
| Histopathology | Core needle biopsy or excision — fibrovascular fronds lined by two cell layers (epithelial + myoepithelial); no atypia in benign papilloma |
Ductography (galactography): instillation of contrast into the discharging duct to outline the filling defect — largely abandoned in most centres due to poor diagnostic yield. (Bailey & Love 28e)
Ductoscopy: microendoscopic inspection of the duct interior — technically feasible but not standard practice. (Bailey & Love 28e)
Cytology of nipple discharge: poor yield for cancer detection — largely abandoned. (Bailey & Love 28e)
Treatment — Based on Type and Clinical Setting
1. SOLITARY CENTRAL INTRADUCTAL PAPILLOMA (Most Common)
A. Surgical Treatment — MICRODOCHECTOMY (Gold Standard)
(Bailey & Love 28e, Chapter 58; Pye's Surgical Handicraft 22e; Berek & Novak's Gynaecology)
Microdochectomy = excision of the single involved major lactiferous duct and its papilloma.
Indications:
- Patient >40 years with blood-stained or serous nipple discharge
- Any age with abnormal mammogram / USS findings
- Persistent discharge causing distress
- Discordant radiological-pathological findings on core biopsy
- Co-existing ipsilateral breast cancer (upstaging risk >20%)
- Atypia present on biopsy
Operative Technique (Pye's Surgical Handicraft 22e):
- Anaesthesia: Local anaesthesia (preferred — day-case) or general anaesthesia
- Confirm discharge on the day of surgery in the anaesthetic room before proceeding
- Identify the duct: Apply pressure at the trigger point to express discharge; identify the discharging duct orifice at the nipple
- Cannulate: A lacrimal probe is gently inserted into the identified duct orifice and advanced as far as it passes easily (~3 cm); a silk suture is tied firmly at the nipple around the probe to secure it
- Incision: Skin infiltrated with 1:80,000 adrenaline; a periareolar (circumareolar) incision made over the length of the probe
- Dissection: The duct is freed along its entire length from the nipple inward; a segment of 5 cm of major milk duct from the nipple is excised (since most papillomas lie within 5 cm of nipple)
- Papilloma identification: Once freed, the duct is opened — papilloma may be visible as a small friable tannish mass like "miniature broccoli florets on a stalk"
- Wound closure: Careful haemostasis; 4/0 polypropylene skin closure; suction drain only if solid area excised
- Specimen to histopathology: Mandatory — to confirm benign papilloma and exclude DCIS or papillary carcinoma
Key Surgical Principle: Duct removed should be 5 cm in length from the nipple — covers the entire zone where papillomas occur.
B. Non-Surgical (Observation) — Selected Cases Only
(Fischer's Mastery of Surgery 8e)
Conservative management is acceptable only if ALL of the following are met:
- Large-bore core needle biopsy (≤14 gauge) used
- Lesion adequately sampled (>50% removed on biopsy)
- No atypia on histology
- Lesion ≤10 mm (some papers allow up to 15 mm)
- Radiological-pathological concordance — imaging and pathology findings agree
- No co-existing ipsilateral breast cancer
In these carefully selected cases, upgrading rate to cancer is ≤2% — surgical excision not mandatory.
Follow-up if observed: Annual clinical breast examination + annual mammography (or USS if identified on USS); excise if any growth or increased suspicion on follow-up.
2. MULTIPLE DUCT / MULTIDUCT DISCHARGE
Procedure: Hadfield's Major Mammary Duct Excision (Total Duct Excision)
(Bailey & Love 28e)
- All major subareolar ducts excised en bloc through a circumareolar incision
- Indicated when discharge comes from multiple ducts
- Also indicated for duct ectasia causing recurrent nipple discharge or periductal mastitis
3. PERIPHERAL PAPILLOMATOSIS (Multiple Peripheral Papillomas)
(Fischer's Mastery of Surgery 8e)
- Multiple small papillomas in the periphery of the breast (>5 cm from nipple), arising in terminal duct lobular units (TDLUs)
- More common in young women; more likely bilateral
- Significantly higher malignant potential than solitary central papilloma
- Upgrading rate to cancer on excision is significant
- Relative risk of future breast cancer: 3–3.5× (vs. 2.1× for solitary papilloma)
Management:
- Surgical excision of all peripheral papillomatosis lesions
- High-risk surveillance: Clinical breast examination every 6 months + annual mammography + consider annual breast MRI or whole-breast USS
- Discordant lesions always require excision
4. PAPILLOMA WITH ATYPIA
(Fischer's Mastery of Surgery 8e)
- Papilloma containing atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH) on core biopsy
- Always requires surgical excision — upgrading rate to DCIS/carcinoma is significantly higher (~15–20%)
- Relative risk of breast cancer: 4–5×
- High-risk surveillance post-excision
Treatment Algorithm Summary
Intraductal Papilloma (Blood-Stained Nipple Discharge)
↓
Triple Assessment
↓
┌──────────────────────────────────┐
│ │
Single duct Multiple duct
│ │
↓ ↓
Age <40, normal Hadfield's Major
triple assessment Duct Excision
→ Reassure + annual
imaging follow-up
│
Age >40 or
abnormal imaging
↓
Core Needle Biopsy
│
├── No atypia, ≤10mm, concordant, no co-existing Ca
│ → Observation acceptable (≤2% upgrade risk)
│
├── Atypia present / >10mm / discordant
│ → MICRODOCHECTOMY (mandatory)
│
└── Peripheral papillomatosis
→ Surgical excision + High-risk surveillance
Key Exam Points
| Point | Detail |
|---|---|
| Most common cause of bloody nipple discharge | Intraductal papilloma |
| Procedure of choice | Microdochectomy (single duct) |
| Multiduct discharge | Hadfield's major duct excision |
| Duct length excised | 5 cm from nipple (Bailey & Love) |
| Why excise? | To treat AND exclude malignancy (5% of single duct discharges = intraduct cancer) |
| Anaesthesia | Local anaesthesia — day-case preferred |
| Instrument used | Lacrimal probe to cannulate the duct |
| Malignant risk — solitary | RR 2.1× future breast cancer |
| Malignant risk — peripheral papillomatosis | RR 3–3.5× |
| Malignant risk — papilloma + atypia | RR 4–5× |
| Observation safe when | No atypia, ≤10 mm, concordant, large-bore biopsy, no co-existing cancer |
(Sources: Bailey & Love's Short Practice of Surgery 28e; Fischer's Mastery of Surgery 8e; Pye's Surgical Handicraft 22e; Berek & Novak's Gynaecology)
Mastitis and granulomatous mastitis treatment
Mastitis is inflammation of the breast — most commonly puerperal (lactational), managed with antibiotics ± incision and drainage. Granulomatous mastitis is a rare, chronic inflammatory condition requiring steroids or methotrexate in addition to surgery.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
All the content I need is now extracted. Comprehensive answer below.
Mastitis and Granulomatous Mastitis — Treatment
CLASSIFICATION OF MASTITIS
MASTITIS
├── ACUTE (Lactational / Puerperal) ← most common
├── NON-LACTATIONAL (Subacute/Chronic)
│ ├── Periductal mastitis (duct ectasia-related)
│ ├── Idiopathic Granulomatous Mastitis (IGM)
│ └── Tubercular mastitis
└── SPECIFIC / INFECTIVE
├── Tuberculosis
├── Fungal
└── Sarcoidosis
PART 1: ACUTE (LACTATIONAL / PUERPERAL) MASTITIS
(Bailey & Love 28e, Chapter 58; Sabiston 21e)
Aetiology
- Incidence 3–20% of lactating mothers
- Organism: Staphylococcus aureus (commonest); hospital-acquired may be MRSA; Streptococcus species
- Entry: Cracked or retracted nipple → duct entry → stasis in lactiferous ducts → bacterial multiplication → abscess
- Peak times: First month post first delivery (inexperience) + at weaning (engorgement, nipple trauma)
Clinical Features
- Cellulitic stage: Erythema, warmth, tenderness, induration of breast segment; fever, malaise, leukocytosis; difficult breastfeeding
- Abscess stage: Fluctuant lump (deep abscesses may not fluctuate); severe pain; axillary lymphadenopathy
- USS: Cellulitis = increased echogenicity; Abscess = hypoechoic collection with floating debris that shifts with position
MANAGEMENT — LACTATIONAL MASTITIS
Stage 1: Cellulitic Stage (No Abscess)
| Intervention | Details |
|---|---|
| Anti-staphylococcal antibiotics | Cloxacillin / Flucloxacillin (first line); Erythromycin if penicillin allergic; MRSA risk → Clindamycin or Trimethoprim-sulfamethoxazole |
| Continue breastfeeding | From both breasts, 2-hourly; breastfeeding should NOT be stopped — stasis worsens infection |
| Breast emptying | After each feed, express remaining milk to prevent stasis |
| Symptomatic relief | Breast support garment; cold compression; analgesia (paracetamol / ibuprofen) |
| Duration | Antibiotics for 10–14 days |
"Breastfeeding from both breasts should be encouraged 2-hourly, followed by emptying the breast." — Bailey & Love 28e
Stage 2: Abscess Formation
Key principle: Ultrasound-guided aspiration/drainage is now preferred over traditional incision and drainage (I&D). (Bailey & Love 28e)
"Ultrasound-guided drainage gives an excellent cosmetic result, does not hamper breastfeeding, and can be done as a day-care procedure with a high rate of success. Incision and drainage may result in a non-healing milk fistula." — Bailey & Love 28e
| Abscess Size | Management |
|---|---|
| Small (<3 cm, <30 mL pus) | USS-guided needle aspiration (repeat every 2–3 days until resolved); oral antibiotics; continue breastfeeding |
| Large (>3 cm or >30 mL pus) | USS-guided vacuum suction catheter insertion; irrigate with cold normal saline on each visit (cold = analgesia); review alternate days; antibiotics for 14 days; modify antibiotics per culture |
| Multiloculated / failed aspiration | Surgical incision and drainage (I&D) as last resort; radial incision (preserves ducts/nerves); break down loculi with finger; loose pack with gauze |
Stopping breastfeeding is NOT necessary; only indicated if severe MRSA infection with systemic sepsis.
PART 2: NON-LACTATIONAL MASTITIS
A. PERIDUCTAL MASTITIS (Bailey & Love 28e; Sabiston 21e)
- Chronic inflammation around major subareolar milk ducts
- Strongly associated with smoking and diabetes
- Pathogenesis: autoimmune + chemical irritation from stagnant duct secretions
- Organisms: Mixed — Staphylococci, Enterococci, anaerobic Streptococci, Bacteroides, Mycobacteria
Clinical Features:
- Central non-cyclical breast pain
- Purulent nipple discharge
- Subareolar tender mass/abscess
- Transverse slit-like nipple retraction (fish-mouth appearance) from periductal fibrosis
- Mammary duct fistula — pus tracks through areolar edge (thick areolar muscles prevent perforation through areola itself)
Management:
| Stage | Treatment |
|---|---|
| Early (pain + erythema) | Warm soaks + oral antibiotics (aerobic + anaerobic cover) |
| Established infection | Co-amoxiclav + Metronidazole / Tinidazole for 2–3 weeks; or Flucloxacillin + Metronidazole; or Ciprofloxacin + Metronidazole |
| Abscess | USS-guided needle aspiration + antibiotics; I&D if aspiration fails |
| Mammary duct fistula | Major mammary duct excision (Hadfield's operation) — excision of entire subareolar duct complex |
| Recurrent infections | Excision of entire subareolar duct complex after acute infection fully resolved + IV antibiotic cover |
| Nipple retraction / profuse discharge | Major mammary duct excision |
| Rarely recurrent | Excision of nipple and areola |
"Repeated infections are treated by excision of the entire subareolar duct complex after the acute infection has resolved completely, together with intravenous antibiotic coverage." — Sabiston 21e
PART 3: IDIOPATHIC GRANULOMATOUS MASTITIS (IGM)
(Bailey & Love 28e; Sabiston 21e; Current Surgical Therapy 14e)
Definition and Key Facts
- Benign, self-limiting, chronic inflammatory breast disease of unknown aetiology
- Occurs in young parous women (within first few years after pregnancy)
- More common in Hispanic, Middle Eastern, South Asian, and Southeast Asian populations
- Possible association with Corynebacterium kroppenstedtii infection
- Mimics cancer clinically and radiologically — triple assessment mandatory
Histology
- Non-caseating granulomas with chronic inflammation centred on lobules (lobulo-centric distribution)
- Epithelioid histiocytes, multinucleated giant cells, lymphocytes
- No caseation (unlike TB) — distinguishes from tuberculosis
Differential Diagnosis (Must Exclude)
| Condition | Distinguishing Feature |
|---|---|
| Tuberculosis | Caseating necrosis; AFB positive; GeneXpert MTB/RIF positive; respond to anti-TB drugs |
| Sarcoidosis | Non-caseating granuloma but systemic disease; elevated ACE; hilar lymphadenopathy |
| Foreign body granuloma | History of implants/injections |
| Carcinoma | Malignant cells on biopsy; no granuloma |
| Wegener's granulomatosis | c-ANCA positive |
Investigations
- Triple assessment: Clinical + USS/Mammogram + core needle biopsy
- Biopsy essential: Establishes diagnosis; must send for:
- Histopathology (granuloma characteristics)
- Gram stain + culture (bacteria)
- Ziehl-Neelsen / AFB stain + culture (TB)
- GeneXpert MTB/RIF (rapid TB detection)
- Fungal stain + culture
- CT chest/abdomen: Rule out sarcoidosis, TB foci elsewhere
- Serum ACE, calcium: If sarcoidosis suspected
MANAGEMENT OF IGM
Management is multimodal and often prolonged. The disease is self-limiting but can recur and persist for months-years. (Bailey & Love 28e; Sabiston 21e; Current Surgical Therapy 14e)
Step 1: Treat Infection if Present
- NSAIDs for symptomatic relief
- Antibiotics if infection/abscess present:
- Doxycycline / Clindamycin / Azithromycin / Levofloxacin (directed at Corynebacterium species)
- Culture-driven antibiotic therapy preferred
- Some advocate alternating antibiotics monthly
- Drainage of abscess if present (USS-guided aspiration preferred)
Step 2: Anti-inflammatory / Immunosuppressive Therapy (Mainstay)
| Drug | Role | Details |
|---|---|---|
| Prednisolone (oral) | First-line steroid | Effective; dose 0.5–1 mg/kg/day; taper over weeks-months; helps regression; risk of exacerbation on taper |
| Topical steroids | Adjunct / mild cases | Applied to skin over affected area; less systemic effect |
| Intralesional steroid injection | Emerging option | Direct injection into mass; "promising results" (Sabiston 21e); minimal systemic side effects |
| Methotrexate | Second-line / steroid-sparing | For patients unable to tolerate steroids or who have exacerbation on steroid taper; weekly low-dose methotrexate (10–25 mg/week) + folic acid; effective in persistent/refractory IGM |
"In cases of persistent symptoms or progression, treatment with prednisolone (oral or topical) with or without methotrexate has helped in regression of IGM." — Bailey & Love 28e
"Medical management includes use of steroids, methotrexate, and/or antibiotics. Surgical excision may be warranted for complicated or refractory cases." — Current Surgical Therapy 14e
"Surgical management is not recommended because it might result in an open, poorly healing wound." — Sabiston 21e
Step 3: Surgical Treatment (Selected/Refractory Cases)
- Not recommended routinely — wound healing is poor, recurrence rates high, cosmetic outcomes poor
- Indications for surgery:
- Mammary duct fistula → Major milk duct excision
- Chronic abscess cavity with recurrence → Excision of abscess cavity
- Refractory disease not responding to medical treatment
- Inability to exclude malignancy despite adequate biopsy
- Avoid wide excision — results in open wounds and poor healing
Important Point — TB Mastitis in Endemic Regions
"In countries where TB is endemic, care should be taken to avoid administering anti-tuberculous therapy as a blanket treatment to all patients with granulomatous mastitis. Anti-tuberculous treatment should only be given to patients with evidence of TB on imaging, histopathology or microbiological analysis and GeneXpert® MTB/RIF." — Bailey & Love 28e
PART 4: TUBERCULAR MASTITIS (Bailey & Love 28e)
- Uncommon; spread from axillary/internal mammary nodes, rib osteitis, pleural cavity, or haematogenous
- Presents with multiple chronic abscesses and sinuses, bluish skin discolouration
- Histology: Caseating epithelioid granuloma (unlike IGM which is non-caseating)
- Send: ZN stain, GeneXpert MTB/RIF, mycobacterial culture
- Treatment: Anti-tuberculous chemotherapy for 6–9 months (standard 4-drug DOTS regimen)
- Healing usual but delayed; leaves puckered scars
Treatment Summary Table
| Type | Key Treatment |
|---|---|
| Lactational mastitis — cellulitic | Antibiotics (flucloxacillin) + breastfeeding + breast emptying |
| Lactational abscess | USS-guided aspiration (preferred) ± suction catheter; I&D only if failed aspiration |
| Periductal / non-lactational mastitis | Co-amoxiclav + Metronidazole; major duct excision for fistula/recurrence |
| IGM — mild/infective | NSAIDs + antibiotics (doxycycline/clindamycin) |
| IGM — persistent/moderate-severe | Oral prednisolone ± intralesional steroids |
| IGM — steroid-refractory | Methotrexate (+ folic acid) |
| IGM — fistula/abscess recurrence | Surgical excision (selected cases only) |
| Tubercular mastitis | Anti-TB chemotherapy 6–9 months (DOTS) |
(Sources: Bailey & Love's Short Practice of Surgery 28e; Sabiston Textbook of Surgery 21e; Current Surgical Therapy 14e)
Galactocele ,duct ectasia , fibroadenosis
Searching sources...
Finding Sources
Finding Sources
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.